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Abstract 
Hepatocytes are dynamic cells that upon injury can alternate between non-dividing 
differentiated and dedifferentiated proliferating states in vivo. However, in 2D 
cultures primary human hepatocytes rapidly dedifferentiate resulting in the loss of 
hepatic functions which significantly limits their usefulness as in vitro model of liver 
biology, liver diseases as well as drug metabolism and toxicity. Thus, understanding 
the underlying mechanisms and stalling of the dedifferentiation process would be 
highly beneficial to establish more accurate and relevant long-term in vitro hepatocyte 
models. Here, we present comprehensive analyses of whole proteome and 
transcriptome dynamics during the initiation of dedifferentiation during the first 24 
hours of culture. We report that early major rearrangements of the non-coding 
transcriptome, hallmarked by increased expression of snoRNAs, lncRNAs, miRNAs, 
and ribosomal genes, precede most changes in coding genes during dedifferentiation 
of primary human hepatocytes and we speculated that these modulations could drive 
the hepatic dedifferentiation process. To functionally test this hypothesis, we globally 
inhibited the miRNA machinery using two established chemically-distinct 
compounds, acriflavine and poly-L-lysine. These inhibition experiments resulted in a 
significantly impaired miRNA response and, most importantly, in a pronounced 
reduction in the downregulation of hepatic genes with importance for liver function. 
Thus, we provide strong evidence for the importance of ncRNAs, in particular 
miRNAs, in hepatic dedifferentiation, which can aid the development of more 
efficient differentiation protocols for stem cell-derived hepatocytes and broaden our 
understanding of the dynamic properties of hepatocytes with respect to liver 
regeneration. 
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Conclusion: miRNAs are important drivers of hepatic dedifferentiation and our 
results provide valuable information regarding the mechanisms behind liver 
regeneration and possibilities to inhibit dedifferentiation in vitro. 
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Introduction 
Upon liver injury, hepatic cells proliferate and rapidly regenerate large parts of the 
damaged organ in vivo1. Different mechanisms of liver regeneration have been 
described in different injury models. Under most injuries, such as partial 
hepatectomy, the liver regenerates by self-duplication of hepatocytes2. Yet, when 
hepatocyte proliferation is compromised, the formation of duct-like “oval cells” with 
a mixed mesenchymal and epithelial expression signature has been observed3. These 
progenitor cells are assumed to originate from the terminal branches of the 
intrahepatic biliary system4 and seminal work demonstrated that these cells can give 
rise to hepatocytes5. Yet, recent studies in mouse models of chronic liver insults 
indicated that new hepatocytes originated from pre-existing hepatocytes rather than 
from distinguished non-parenchymal stem-cell populations6,7. One explanation for 
this ostensible discrepancy might be the capacity of hepatocytes to undergo reversible 
ductal metaplasia, which opens the possibility that hepatocyte-derived progenitor cells 
expressing biliary markers are mistaken for progenitor cells of biliary origin8,9.  
 
In vitro in 2D monolayer cultures, primary human hepatocytes (PHH) rapidly lose 
their phenotype and dedifferentiate into fetal-like progenitor states with drastically 
reduced liver-specific functionality, which hampers their usefulness for studies of 
liver biology, liver disease, drug metabolism and toxicity10,11. Most importantly, PHH 
rapidly lose expression of important liver-specific genes, such as cytochrome P450 
(CYP) enzymes, phase 2 enzymes and transporters12. Therefore, decipherment and 
eventual inhibition of the dedifferentiation process could allow for more accurate and 
relevant long-term in vitro hepatocyte models. Furthermore, mechanistic 
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understanding of the dedifferentiation process can guide the development of more 
efficient differentiation protocols for stem cell-derived hepatocytes. Until now 
however, the molecular cues that initiate the dedifferentiation process and its 
mediators that render hepatocytes capable to respond so rapidly to a changing cellular 
environment have remained elusive. 
 
Changes in transcript levels can be modulated by non-coding (nc)RNA species such 
as micro (mi)RNAs, small nucleolar (sno)RNAs, and long non-coding (lnc)RNAs13. 
miRNAs are short single-stranded RNAs that associate with the RNA-induced 
silencing complex (RISC) by binding to AGO proteins, downregulating protein output 
of complementary transcripts by translational inhibition or transcript degradation14. 
An in silico study using 79 human livers showed that levels of 275 miRNAs 
correlated inversely with expression patterns of their putative hepatic target genes15. 
Furthermore, analyses of miRNA expression during the differentiation of stem cells to 
hepatocyte-like cells implicated dozens of miRNAs in these developmental 
programs16. Yet, miRNA dynamics during hepatocyte dedifferentiation remain to be 
elucidated. Combined, these data suggest that miRNAs are of paramount importance 
for liver function and hepatic differentiation and merit detailed investigation. 
 
snoRNAs guide modifications of other ncRNA species such as ribosomal RNAs, 
thereby contributing to the remodeling of the cell’s translational capabilities17,18. 
Furthermore, many snoRNAs harbor sno-derived (sd)RNAs that are commonly 
conserved across species from vertebrates to plants19. Interestingly, some sdRNAs 
have been shown to impact alternative splicing and are implicated in disease (e.g. 
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SNORD115 in Prader-Willi syndrome20), while others control levels of target 
mRNAs21,22. 
 
lncRNAs are a rapidly growing class of ncRNAs that can influence protein output by 
regulating transcription of nearby or distal genes, impacting splicing, RNA stability or 
translation, as well as acting as miRNA decoys (see 23 and references therein). 
lncRNAs are difficult to study en bloc because (i) they cannot be predicted solely on 
their sequence and (ii) the functionality and molecular mode of action of most 
lncRNA family members remains poorly understood. 
 
While mounting evidence indicates important roles for ncRNAs in hepatic 
dedifferentiation, their dynamics and functional effects have not been quantitatively 
assessed with high temporal resolution. Therefore, we here thoroughly characterized 
changes in coding and non-coding transcriptomes during dedifferentiation of PHH 
using unsupervised whole transcriptome analyses. We detected massive alterations of 
ncRNA signatures that preceded changes in coding transcripts during later stages of 
dedifferentiation. In order to investigate whether these ncRNA modulations could 
drive the dedifferentiation process, we established a miRNA inhibition assay using 
two chemically-distinct inhibitors that interfere with different nodes of the miRNA-
processing pathway. We found that miRNA inhibition significantly reduced the early 
miRNA response and the loss of hepatic marker genes. Moreover, whole-
transcriptome analyses revealed that gene expression changes during dedifferentiation 
in inhibitor-treated samples were globally reduced, thus providing strong evidence for 
the importance of ncRNAs, in particular miRNAs, in hepatic dedifferentiation. 
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Materials and Methods 
Hepatocytes cultures  
Fresh hepatocytes obtained from patients subject to liver resections at Huddinge 
University Hospital, Stockholm, Sweden were used for the dedifferentiation 
experiments (Table 1). The hepatocytes obtained from patient livers were isolated as 
previously described24. Use of liver specimens was approved by the Ethics Committee 
at Karolinska Institutet and written informed consent was obtained from all donors of 
liver material. Hepatocytes were seeded into plates coated with 5 µg/cm2 Rat Tail 
Collagen Type I (Corning) in culture medium (Williams E medium supplemented 
with 2mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 10 µg/ml 
insulin, 5.5 µg/ml transferrin, 6.7 ng/ml sodium selenite, 100nM dexamethasone) with 
10% FBS. After two hours of attachment, the medium was replaced with serum-free 
culture medium. Time point 0 (t0) is defined as immediately before plating. The other 
time points denote time passed since plating.  
 
miRNA inhibition experiments 
Cryopreserved hepatocytes were thawed according to the supplier’s protocol 
(BioreclamationIVT) and cultured as above. Cells were treated with 2 (low), 10 
(medium) or 30 µM (high) AF or 1 (low), 5 (medium) or 15 µM (high) PLL as 
indicated.  
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Statistical analyses 
Unsupervised hierarchical clustering and principal component analysis of genes was 
performed in Qlucore Omics Explorer 3.2. Differentially expressed genes were 
determined using an F-test across all time points (omnibus ANOVA). Multiple testing 
correction was performed using the Benjamini-Hochberg algorithms with a false 
discovery rate (FDR) of 1%. For correlations between mRNA and protein responses, 
Pearson correlation coefficients were computed on fold changes of mRNA and 
protein abundances at the respective time points relative to t0. Pathway analyses were 
performed using Ingenuity Pathway Analysis (IPA, QIAgen). Global gene expression 
data from control and AF/PLL-treated PHH were used to extract miRNA expression 
levels that were further normalized to t0. Corresponding fold-change values for 
upregulated miRNAs were interpret d in the microRNA Target Filter of IPA to find 
corresponding downregulated mRNA targets from whole transcriptome data of the 
same samples. Resulting gene lists were submitted to the WebGestalt online resource 
for KEGG pathway analysis25.  
 
Extended methods are available in the Supporting Information online. 
 
 
Results 
Transcriptomic changes occur in two distinct phases of molecular remodeling 
during hepatocyte dedifferentiation. 
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To decode the changes in transcriptional profiles during dedifferentiation of PHH we 
assessed gene expression dynamics using whole transcriptome approaches in which 
coding as well as non-coding RNA transcripts were analyzed with high temporal 
resolution (n=3-5 livers per time point). In total, we identified 4,042 transcripts that 
were significantly differentially expressed during the first 24 hours of 
dedifferentiation after multiple testing correction (FDR=0.01, Figure 1A). 
Importantly, we detected two distinct phases of transcriptomic changes: an early 
response (from 30 minutes until 4 hours) and a late response (between 16 and 24 
hours) that were characterized by changes in two distinctively different sets of genes 
(Figure 1B). 
 
Pathway analyses of differentially expressed transcripts over time revealed significant 
modulations of cytokine and signal transduction pathways such as IL-1 and PKA 
signaling as well as PPARα/RXRα transcriptional responses already after 30 minutes 
followed by major restructuring of metabolic pathways evidenced by changes in 
oxidative phosphorylation and mitochondrial dysfunction (Figure 1C and Supporting 
Table 2). The earliest responses were detected in genes involved in innate immunity, 
whereas expression changes in genes involved in absorption, distribution, metabolism 
and excretion (ADME) of drugs as well as cell adhesion were found at later phases 
(Supporting Figure 1). Furthermore, alterations in EIF2 signaling and protein 
ubiquitination pathways suggest modulations of protein turnover. Significant changes 
at later stages of hepatic dedifferentiation included major metabolic pathways such as 
the TCA cycle, ketogenesis, the urea cycle and fatty acid metabolism.  
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To probe whether transcriptomic alterations were faithful markers of phenotypic 
changes during dedifferentiation, we performed whole-proteome analyses. Overall, 
we detected less expressed proteins than coding transcripts (2,356 proteins vs. 20,667 
transcripts) most likely due to the low expression levels of many proteins such as 
transcription factors as well as the relatively lower sensitivity of mass spectrometry-
based methods. To assess the agreement between responses on mRNA and protein 
level, we correlated transcriptomic and proteomic changes. Interestingly, while 
correlations were poor after 4 hours (r=0.16), they improved substantially after 24 
hours (r=0.72; Figure 1D). Notably, abundances of most CYP proteins, such as 
CYP2A6, CYP2B6, CYP2C19 and CYP2D6 were only moderately affected after 24 
hours of dedifferentiation in agreement with long half-lives of this class of 
proteins11,26, whereas their corresponding transcript levels were strongly reduced. The 
overall proteomic changes followed transcriptomic profiles with the exception of fatty 
acid β-oxidation, which was first detected at the proteomic levels (Figure 1C and 
Supporting Table 3). We concluded that changes in transcriptomic signatures translate 
into phenotypic changes during early hepatocyte dedifferentiation and are thus 
suitable markers to study underlying regulatory processes.  
 
When we categorized differentially expressed transcripts into protein-coding genes, 
miRNAs, lncRNAs, snoRNAs and ribosomal genes (rRNAs and ribosomal proteins, 
we observed that changes in these ncRNA classes peaked at 4 hours, whereas an 
impact on coding genes was predominantly observed later (Figure 2). Furthermore, 
whereas protein-coding genes showed a tendency to be rather downregulated during 
dedifferentiation (52.4% downregulated), non-coding genes were predominantly 
upregulated (Figure 2C-F). Interestingly, among the different classes of ncRNAs, the 
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dynamics and direction of regulation of lncRNAs Figure 2D) more closely resembled 
the temporal and directional profiles of coding genes (Figure 2B), possibly, at least in 
part, because of a positive correlation between the transcription of lncRNA and their 
proximal protein-coding genes27.  
 
miRNA levels are substantially reduced in primary hepatocytes upon small 
molecule inhibition of the miRNA machinery. 
Based on the dynamics and direction of transcriptomic changes, we hypothesized that 
modulations of the ncRNAome could be causal for alterations observed in protein-
coding genes and thus for the loss of the hepatocyte phenotype. To test this 
hypothesis, we focused specifically on miRNAs since miRNA biogenesis and action 
is mediated by only few genes that constitute the miRNA processing machinery. We 
inhibited the miRNA pathway at two distinct nodes using two well-characterized, 
chemically distinct compounds, acriflavine (AF) and poly-L-lysine (PLL). While PLL 
is reported to inhibit the association of pre-miRNAs to Dicer, AF impairs RISC by 
inhibition of miRNA binding to AGO family proteins28. No toxicity of AF and PLL 
was detected at any of the concentrations tested after 4 hours (p>0.15 for all, 
Supporting Figure 2). After 24 hours, PLL affected viability only minimally even at 
high concentrations (viability PLLhi = 86%±4%), whereas AF was more toxic with 
increasing concentrations.  Consequently, we chose to focus on samples treated with 
low AF (viability AFlow = 71%±4%) and high PLL concentrations, respectively. 
 
First, we assessed the effect of AF and PLL on expression levels of a set of specific 
miRNAs with important roles in liver function (Figure 3A). Hepatic miRNAs miR-
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103 and miR-107 that regulate insulin sensitivity29 were upregulated during 
dedifferentiation, an effect that was inhibited by PLL and to a lesser extent by AF. 
Similarly, levels of the pro-proliferative miRNAs miR-21, miR-122 and miR-221, 
which target the cell cycle inhibitors BTG2, HMOX1 and CDKN1B30-32, respectively, 
were rapidly increased, consistent with an initiation of the hepatic regeneration 
program. No significant changes were detected in the anti-proliferative miR-22 and 
miR-26a (p>0.05 for both miRs after 4 and 24h compared to t0, data not shown). Yet, 
levels of the anti-proliferative miRNA miR-33a, a direct inhibitor of CDK6 and 
CCND1
33 were massively increased during dedifferentiation. Importantly, PLL and 
AF generally reduced the burst of miRNA expression observed in untreated samples, 
indicating that small molecule inhibition of the miRNA machinery might be an 
effective means to reduce overall miRNA levels.   
 
Next, we assessed the effect of AF and PLL on miRNA levels on a global scale and 
detected a decrease in overall miRNA expression levels (Figure 3B). While after 4h, 
12% (AF) and 7% (PLL) of all expressed miRNA were downregulated >1.5-fold, 
after 24h 32% (AF) and 43% were downregulated upon AF and PLL treatment, 
respectively compared to control at the same time point (Figure 3C), thus confirming 
that inhibition of the miRNA machinery results in substantially reduced levels of 
mature miRNAs in the cell within the time frame studied.  
 
Inhibition of the miRNA machinery delays the loss of hepatic differentiation 
markers 
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To address the impact of miRNA inhibition during hepatic dedifferentiation, we 
assessed whether AF- and PLL-mediated miRNA inhibition impacts hepatocyte 
dedifferentiation kinetics. We analyzed the changes in expression levels of 110 genes, 
including phase I and phase II enzymes, transporters, nuclear receptors and other 
genes with importance for hepatic functionality (Figure 4). We found that expression 
of these hepatic genes decreased rapidly in untreated hepatocytes with some genes 
being downregulated by up to 97% (SLCO1B1 and SLCO1B3) after only 4 hours of 
culture (Figure 4B). Importantly, inhibition of the miRNA machinery largely 
mitigated the loss of marker gene expression (Figure 4 and qPCR validations in 
Supporting Figure 3). Consistent with the downregulation of hepatic genes during 
dedifferentiation, expression levels of the vast majority of these genes were found to 
be increased compared to untreated controls at the same time point (Figure 4C). We 
noticed that effect sizes of our treatments differed substantially between genes, as 
expression levels of CYP3A4 and HNF4A increased only to a limited extent, whereas 
the effect on CYP2C8 and CYP2C9 was much more prominent (Figure 4A and 
Supporting Figure 3). 
 
To substantiate the conceptual role of miRNAs in dedifferentiation, we specifically 
inhibited miR-103, a miRNA that was strongly affected by AF and PLL treatment, 
using specific antagomiRs (Supporting Figure 3). We found that expression of its 
bona fide target gene CYP2C834 was significantly increased, thus providing evidence 
that candidate miRNA inhibition can contribute to a delay of dedifferentiation when 
only considering its particular target transcript subset.  
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We conclude that while the extent and kinetics to which hepatic marker genes are 
regulated by miRNAs can differ, inhibition of the miRNA machinery has overall 
profound effects on dedifferentiation at the molecular level. 
 
 
miRNA inhibition reduces overall hepatocyte dedifferentiation. 
To assess the impact of miRNA inhibition during dedifferentiation beyond alterations 
of expression patterns in hepatic markers, we correlated expression fold-changes for 
each gene after 4 hours and 24 hours of dedifferentiation in control with PLL- and 
AF-treated samples (Figure 5). The slope of the regression lines indicates the extent 
of dedifferentiation for a given treatment and time-point relative to control. After only 
4 hours, transcriptomic signatures were significantly different between control and 
inhibitor-treated samples (p<0.0001, F-test comparing control and AF/PLL regression 
lines). In inhibitor-treated samples, expression levels were generally less affected 
compared to control (95% CI of regression slopes: (aPLL,4h) = 0.7-0.71; 95% CI(aAF,4h) 
= 0.76-0.76; Figure 5A,B), an effect became even more pronounced over time as 
transcriptomic fingerprints more closely resembled samples prior to dedifferentiation 
than dedifferentiated control samples after 24 hours of culture (95% CI(aPLL,24h) = 
0.24-0.25; 95% CI(aAF,24h) = 0.27-0.28; Figure 5C,D). Furthermore, when considering 
only genes that were found to be differentially expressed during dedifferentiation (see 
Fig. 1), we found that changes in their gene expression signatures, indicative of 
dedifferentiation were drastically reduced (Supporting Figure 5).  
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While transcriptomes of treated and control samples correlated significantly 
(p<0.0001 for both AF and PLL, F-test), the expression levels of some individual 
genes differed drastically. When considering only those genes whose expression 
levels were increased >10-fold in miRNA-inhibitor treated samples, we found them to 
be enriched in both AF- and PLL-treated samples in acute phase response signaling, 
the complement system, FXR/RXR and PXR/RXR activation, thus suggesting 
prolongation of immune response signaling and a positive effect on liver specific 
functionality (see Supporting Table 4). Genes that were downregulated >10-fold in 
inhibitor-treated samples were enriched in adherence junction, actin cytoskeleton and 
ILK signaling. Again, very similar results were obtained using both AF and PLL. 
 
Interestingly, transcriptomic changes in response to inhibition of the miRNA 
machinery were mostly symmetrically distributed in up- and downregulated genes 
compared to control (Supporting Fig. 6). Nevertheless, the fraction of genes that were 
downregulated less in treated compared to control samples was enriched especially 
after 24 hours (red columns, Supporting Fig. 6).  
 
We then analyzed the effects of AF and PLL specifically on the miRNAome and 
associated pathways by matching upregulated miRNAs with their predicted target 
transcripts within the same experiment (Table 2). In control samples, metabolic 
pathways, protein processing in the endoplasmic reticulum and fatty acid metabolism 
were most significantly affected. Importantly, significantly fewer genes of the 
respective networks were targeted in AF- and PLL-treated samples in agreement with 
overall reduced dedifferentiation. 
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Combined, our data indicate that inhibition of the miRNA machinery results in drastic 
changes in the hepatic dedifferentiation program, strongly reducing the loss of hepatic 
markers and mitigating alterations in adherence junction signaling and cytoskeletal 
remodeling, suggesting a key role for miRNAs in driving the underlying molecular 
processes.  
 
 
Discussion 
Hepatocytes are very dynamic cells in vivo that can rapidly switch between non-
dividing states during liver homeostasis and dividing states upon liver injury. During 
this process, they undergo a wide range of molecular changes including alterations in 
marker gene expression, indicating that they can transiently dedifferentiate into more 
progenitor-like states8,9. Following proliferation, cells redifferentiate and thus 
replenish the pool of mature hepatocytes within the regenerating organ9. Mechanistic 
understanding of how hepatocytes can alter their differentiation states can give 
valuable information for the generation of hepatocytes from stem cells. 
Dedifferentiation also occurs in vitro as rapid loss of marker gene expression and 
hepatic functionality are observed when PHH are placed in 2D culture. This loss of 
liver functions is detrimental in drug discovery and assessment programs where new 
chemical entities are tested e.g. for metabolism, toxicity, drug interactions and 
induction, as results form the basis for the development of clinical programs.  
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In this study we demonstrate that gradual changes in genes related to immunity and 
energy balance occurred during the first 4 hours of culture, followed by later changes 
in major metabolic pathways. Notably, the response at the proteomic level mostly 
overlapped and followed transcriptomic changes with respect to pathway 
enrichments, indicating that transcriptomic changes are overall faithful markers of 
phenotypic alterations in the early phases of hepatocyte dedifferentiation. 
Interestingly, transcriptomic and proteomic responses correlated only very weakly 
after 4 hours (r=0.16), probably at least in part due to the widespread transcriptomic 
remodeling, which has not been fully translated to the level of protein abundances. In 
contrast, correlations after 24 hours are significantly higher (r=0.72) and similar to 
values reported for murine liver (r=0.6 for mRNA vs. protein copy numbers)35. 
 
When expression changes were resolved by gene class, the highest number of 
differentially expressed genes was detected after 4 hours of culture. Notably, the 
upregulation of ribosomal genes was paralleled by an activation of mTOR and EIF2 
signaling, which primes cells for increased mRNA translation, foreshadowing a 
massive remodeling of cellular functionality and phenotypes36,37. Furthermore, the 
canonical function of snoRNAs is the 2’-O-methylation and pseudouridylation of 
ribosomal RNAs, again hinting at an overall translational activation18.  
 
To functionally test the role of miRNAs as potential drivers of the dedifferentiation 
program, we used AF and PLL. PLL inhibits Dicer-dependent processing of pre-
miRNA molecules into mature miRNAs, manifesting in reduced miRNA levels28, 
which is consistent the global reduction in miRNA levels (Figure 3). In contrast, AF 
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blocks the binding of mature miRNA molecules to AGO family proteins and hence 
does not directly impact miRNA levels28. Yet, previous studies showed that unbound 
miRNAs are less stable than miRNAs bound to RISC38, which could explain the 
variability in expression levels of the different miRNAs. The extent of reduction in 
expression upon inhibitor treatment varied substantially between different miRNAs. 
While miR-33a levels were below detection limit upon PLL treatment already after 4 
hours, levels of miR-21 were not affected, suggesting vastly different miRNA half-
lives. This finding contrasts previous studies that reported miRNAs half-lives to range 
from hours to days, indicating that the inherent stability might differ miRNA species 
but also between primary cells during major remodeling processes and cell cultures in 
static conditions39. Notably, the slow kinetics of genetic or siRNA-based approaches 
for miRNA-inhibition combined with long half-lives of protein components of the 
miRNA machinery40 render such tools inadequate to inhibit miRNA action within the 
timeframe in which molecular changes occur. Therefore, small molecule inhibition 
presents currently the only viable option to perturb rapidly enough.  
 
While hepatocytes proliferate in vivo after partial hepatectomy, dedifferentiation in 
vitro is not paralleled by hepatic proliferation. Even when cells are stimulated with 
growth factors, proliferation quickly ceases and cells enter cell cycle arrest41. This 
discrepancy between proliferative responses in vivo and in vitro correlates with the 
differences in response of miR-33 whose expression is reduced during liver 
regeneration, relieving inhibition of CDK6 and Cyclin D1 expression thereby 
supporting entry of cells into mitosis. In contrast, miR-33a expression is strongly 
increased in vitro (Figure 3A), hampering cell cycle entry. Thus, inhibition of miR-
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33a might present a novel approach to stimulate proliferation of primary hepatocytes 
in vitro. 
 
Importantly, analyses of expression kinetics of 110 hepatic genes revealed that their 
downregulation was mostly reduced with both miRNA inhibitors, yet to varying 
extents (Figure 4 and Supporting Fig. 3). While the decrease in e.g. CYP2A6, 
CYP2C8, CYP2C9, CYP2D6 and SLC22A1 expression was strongly reduced, only 
minor elevations of transcript levels were observed for CYP3A4. Our results are in 
agreement with previous experimental findings showing that CYP2C8 (miR-103/107) 
and CYP2C9 (miR-128) are strongly regulated by miRNAs34,42. Furthermore, a recent 
screen for miRNAs as modulators of CYP3A4 activity revealed only minor 
inhibition43 consistent with the low but significant increase in CYP3A4 transcript 
levels observed here. To validate these findings, we inhibited miR-103 using a 
specific antagomiR and found that its bona fide target gene CYP2C8 was upregulated 
accordingly during dedifferentiation (Supporting Figure 4). These experimental 
indications about the extent to which miRNAs regulate ADME gene expression 
further incentivizes their therapeutic targeting and warrants investigations of the 
impact of miRNAs on the disposition of co-administered drugs44. Yet, further studies 
are required to quantify the recruitment of specific miRNAs to the RISC, as bound 
miRNAs might be more faithful reporters for regulatory load during liver regeneration 
than overall transcriptional levels45.  
 
Combined, our data indicate that (i) an upregulation of a multitude of miRNAs 
precedes the loss of hepatic marker gene expression and (ii) that this dedifferentiation 
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is diminished when the miRNA pathway is either generally inhibited or when 
candidate miRNAs are blocked in a targeted approach. Importantly though, not all 
hepatic markers that we analyzed responded to miRNA inhibition with similar 
magnitude indicating that also other regulatory mechanisms such as short transcript 
half-lives potentially contribute to a rapid downregulation of transcript levels.  
 
When we correlated expression fold-changes in control and miRNA inhibitor-treated 
samples, we found that the ameliorating effect on dedifferentiation increased after 24 
hours, possibly due to indirect effects such as the regulation of core transcription 
factors (Figure 5). Most considerably “rescued” pathways by miRNA inhibition were 
complement system and cytokine signaling, cytoskeleton, cell adhesion, and hepatic 
expression programs such as PXR/RXR activation (Figure 5C,D), thus mirroring 
deregulated pathways during dedifferentiation and indicating an overall improvement 
of hepatic phenotype. While the data presented here indicates that miRNA changes 
constitute an integral part of the hepatic dedifferentiation program, the upstream cues 
that trigger the initiation of dedifferentiation, remain to be elucidated.  To this end, a 
variety of stimuli have been suggested, including harsh hepatocyte isolation 
conditions as such, serum depletion, alterations in cell-ECM or cell-cell contacts and 
exposure to non-physiological stiffness of culture substratum46,47.  However, as 
hepatocytes retain their functionality when cultured as 3D spheroids in serum-free 
conditions48, perturbations of cell-ECM or cell-cell contacts and exposure to non-
physiological stiffness of culture substratum appear to be most likely causes.  
 
Page 24 of 93
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
HEP-16-0352.R2 25
The data presented here might exemplify a more general biological principle of 
dynamic cellular adaptation. miRNAs might serve as the tool of choice for the cell to 
quickly degrade particular mRNA and/or inhibit their translation, especially those 
with a long half-life, and thus facilitate expeditious remodeling of the transcriptomic 
inventory when rapid adjustments are needed in response to changes in environment 
or specific signaling cues as seen in other contexts, such as T-cell activation49. 
Furthermore, as miRNAs can have pleiotropic targets thereby diversifying an 
incoming stimulus into a wide range of downstream targets, thus serving as a 
molecular signal amplifier. 
 
In conclusion, our results indicate a novel role for miRNAs in hepatic processes and 
implicate them as important drivers of hepatic dedifferentiation. As such, these 
findings are of importance for understanding mechanisms of stem cell differentiation 
into hepatocytes as well as for liver regeneration, during which similar 
dedifferentiation processes might occur in vivo. Furthermore, the data presented here 
might highlight a more wide-spread miRNA-mediated dynamic control of 
transcriptional profiles that warrants further investigations. 
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Supporting Information 
Additional Supporting information can be found online. 
 
 
Figure 1: Profiling of early events in hepatic dedifferentiation on transcriptomic 
and proteomic level reveals overall molecular rearrangements.  (A) Heatmap 
visualization of mean-centered, sigma-normalized expression data of differentially 
expressed genes during the first 24 hours of hepatocyte dedifferentiation (n=4,042, 
FDR=0.01) reveals an early response in which expression changes accumulate 
progressively during the first 4 hours and (ii) a later response in which a different set 
of genes was affected. Numbers in the colored circles indicate the respective 
hepatocyte donor (Table 1). (B) Principle component analysis of differentially 
expressed genes shown in A resulted in the identification of two orthogonal 
components for early and late transcriptomic changes. (C) Pathway analysis of 
differentially expressed genes revealed the temporal order of events. Pathways 
identified as differentially regulated in at least 2 consecutive time points with p<0.05 
on transcriptomic (blue) and proteomic level (red) are shown. (D) Scatter plots 
showing the correlations between mean changes in mRNA levels and the 
corresponding average changes in protein abundances after 4 hours and 24 hours in 
culture. The mean of 3 donors is plotted. 
 
Figure 2: Early changes in non-coding RNAs precede rearrangements of the 
coding transcriptome during hepatocyte dedifferentiation. (A) Stacked column 
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plot visualizing the number of up- and downregulated genes at each time point 
compared to t0. Coding genes are shown in blue, non-coding genes in grey. Small pie 
charts associated to each column indicate the relative fractions of differentially 
expressed non-coding RNAs at the respective time point categorized by gene class. 
Note that the highest number of differentially expressed genes was found after 4 hours 
and was dominated by upregulated non-coding RNAs. (B-E) Stacked column plots 
showing the profiles of transcriptomic changes resolved by gene class and up- and 
downregulation (dark and light hue, respectively) into protein-coding genes (B), 
miRNAs (C), lncRNAs (D), snoRNAs (E) and ribosomal genes (F). y-axis indicates 
differentially expressed genes. While protein-coding genes were up- and 
downregulated, non-coding genes had a strong bias for upregulation especially at 
early time points.  
 
Figure 3: miRNA expression during hepatocyte dedifferentiation can be 
inhibited using small molecule inhibitors. The miRNA machinery was inhibited 
using acriflavine (AF) and poly-L-lysine (PLL). All expression levels were 
normalized to expression prior to dedifferentiation (t0). (A) Expression of all six 
miRNAs shown were elevated during dedifferentiation in control samples (blue). This 
increase in miRNA levels was mostly inhibited dose-dependently by AF (red) and 
PLL treatment (green). Inhibitor-treated samples were compared with the 
corresponding controls at the same time point using heteroscedastic two-tailed t-tests. 
Error bars indicate s.e. * indicates p<0.05, ** indicates p<0.01. n.d. indicates 
expression below detection limit. N=6 experiments for controls and 3 for inhibitor-
treated samples (B, C) Transcriptomic assessment of miRNA levels upon AF- and 
PLL-treatment. (B) Heatmap displaying expression changes of all detected miRNAs. 
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(C) Column plot showing the fraction of expressed miRNAs that were downregulated 
more than 1.5-fold compared to control at the same time point. In total n=210 
different miRNAs were robustly detected in all samples. 
 
Figure 4: Inhibition of the miRNA machinery ameliorates changes in hepatic 
genes during hepatic dedifferentiation. (A) Heatmap visualization of mean-
centered, sigma-normalized expression data of 110 genes with importance for hepatic 
functionality. Note that while many hepatic genes are rapidly lost in control samples, 
treatment with AF and PLL overall decreases this effect.  (B, C) Dot plot 
representations visualizing the change of expression of the same 110 hepatic genes 
compared to timepoint 0 (B) or to the corresponding control at the same time point 
(C). Notably, CYP2A6, a specialized indicator of hepatic differentiation11, is 
upregulated 8- and 26-fold in AF and PLL-treated samples after 24h, respectively. FC 
= fold change. 
 
Figure 5: Evaluation of overall transcriptomic changes in response to miRNA 
inhibitors reveals drastically reduced dedifferentiation. Scatter log-plots of 
transcriptomic changes (n=61,933 gene products) in control samples versus changes 
in AF- or PLL-treated cultures after 4 h (A-B) and 24 h (C-D). Red and green dots 
highlight genes that are up- or downregulated >10-fold under treatment, respectively. 
These form the basis for the analysis of most affected pathways shown in red and 
green inlet boxes. Solid red lines indicate complete dedifferentiation in control 
samples (slope a=1). Dashed red lines indicate computed regression lines. Note that 
regression line slopes (ainh) can be interpreted as the extent of dedifferentiation and 
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were <1 for all time points and treatments, indicating decreased overall 
dedifferentiation at the systems level. Values for r indicate Pearson correlation 
coefficients.  
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Abstract 
Hepatocytes are dynamic cells that upon injury can alternate between non-dividing 
differentiated and dedifferentiated proliferating states in vivo. However, in 2D 
cultures primary human hepatocytes rapidly dedifferentiate resulting in the loss of 
hepatic functions which significantly limits their usefulness as in vitro model of liver 
biology, liver diseases as well as drug metabolism and toxicity. Thus, understanding 
the underlying mechanisms and stalling of the dedifferentiation process would be 
highly beneficial to establish more accurate and relevant long-term in vitro hepatocyte 
models. Here, we present comprehensive analyses of whole proteome and 
transcriptome dynamics during the initiation of dedifferentiation during the first 24 
hours of culture. We report that early major rearrangements of the non-coding 
transcriptome, hallmarked by increased expression of snoRNAs, lncRNAs, miRNAs, 
and ribosomal genes, precede most changes in coding genes during dedifferentiation 
of primary human hepatocytes and we speculated that these modulations could drive 
the hepatic dedifferentiation process. To functionally test this hypothesis, we globally 
inhibited the miRNA machinery using two established chemically-distinct 
compounds, acriflavine and poly-L-lysine. These inhibition experiments resulted in a 
significantly impaired miRNA response and, most importantly, in a pronounced 
reduction in the downregulation of hepatic genes with importance for liver function. 
Thus, we provide strong evidence for the importance of ncRNAs, in particular 
miRNAs, in hepatic dedifferentiation, which can aid the development of more 
efficient differentiation protocols for stem cell-derived hepatocytes and broaden our 
understanding of the dynamic properties of hepatocytes with respect to liver 
regeneration. 
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Conclusion: miRNAs are important drivers of hepatic dedifferentiation and our 
results provide valuable information regarding the mechanisms behind liver 
regeneration and possibilities to inhibit dedifferentiation in vitro. 
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Introduction 
Upon liver injury, hepatic cells proliferate and rapidly regenerate large parts of the 
damaged organ in vivo1. Different mechanisms of liver regeneration have been 
described in different injury models. Under most injuries, such as partial 
hepatectomy, the liver regenerates by self-duplication of hepatocytes2. Yet, when 
hepatocyte proliferation is compromised, the formation of duct-like “oval cells” with 
a mixed mesenchymal and epithelial expression signature has been observed3. These 
progenitor cells are assumed to originate from the terminal branches of the 
intrahepatic biliary system4 and seminal work demonstrated that these cells can give 
rise to hepatocytes5. Yet, recent studies in mouse models of chronic liver insults 
indicated that new hepatocytes originated from pre-existing hepatocytes rather than 
from distinguished non-parenchymal stem-cell populations6,7. One explanation for 
this ostensible discrepancy might be the capacity of hepatocytes to undergo reversible 
ductal metaplasia, which opens the possibility that hepatocyte-derived progenitor cells 
expressing biliary markers are mistaken for progenitor cells of biliary origin8,9.  
Cell-labeling experiments indicate that the new hepatocytes originate from mature 
hepatocytes rather than from distinguished stem-cell populations2,3. This hepatocyte 
expansion is assumed to involve transient dedifferentiation followed by proliferation 
and redifferentiation, which demonstrates an astonishing plasticity of liver cells 
regarding their differentiation states4,5.  
In vitro in 2D monolayer cultures, primary human hepatocytes (PHH) rapidly lose 
their phenotype and dedifferentiate into fetal-like progenitor states with drastically 
reduced  liver-specific functionality, which hampers their usefulness for studies of 
liver biology, liver disease, drug metabolism and toxicity10,11. Most importantly, PHH 
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rapidly lose expression of important liver-specific genes, such as cytochrome P450 
(CYP) enzymes, phase 2 enzymes and transporters12. Therefore, decipherment and 
eventual inhibition of the dedifferentiation process could allow for more accurate and 
relevant long-term in vitro hepatocyte models. Furthermore, mechanistic 
understanding of the dedifferentiation process can guide the development of more 
efficient differentiation protocols for stem cell-derived hepatocytes. Until now 
however, the molecular cues that initiate the dedifferentiation process and its 
mediators that render hepatocytes capable to respond so rapidly to a changing cellular 
environment have remained elusive. 
 
Changes in transcript levels can be modulated by non-coding (nc)RNA species such 
as micro (mi)RNAs, small nucleolar (sno)RNAs, and long non-coding (lnc)RNAs13. 
miRNAs are short single-stranded RNAs that associate with the RNA-induced 
silencing complex (RISC) by binding to AGO proteins, downregulating protein output 
of complementary transcripts by translational inhibition or transcript degradation14. 
An in silico study using 79 human livers showed that levels of 275 miRNAs were 
inversely correlated inversely with expression patterns of their putative hepatic target 
genes15. Furthermore, analyses of miRNA expression during the differentiation of 
stem cells to hepatocyte-like cells implicated dozens of miRNAs in these 
developmental programs16. Yet, miRNA dynamics during hepatocyte 
dedifferentiation remain to be elucidated. Combined, these data suggest that miRNAs 
are of paramount importance for liver function and hepatic differentiation and merit 
detailed investigation. 
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snoRNAs guide modifications of other ncRNA species such as ribosomal RNAs, 
thereby contributing to the remodeling of the cell’s translational capabilities17,18. 
Furthermore, many snoRNAs harbor sno-derived (sd)RNAs that are commonly 
conserved across species from vertebrates to plants19. Interestingly, some sdRNAs 
have been shown to impact alternative splicing and are implicated in disease (e.g. 
SNORD115 in Prader-Willi syndrome20), while others control levels of target 
mRNAs21,22. 
 
lncRNAs are a rapidly growing class of ncRNAs that can influence protein output by 
regulating transcription of nearby or distal genes, impacting splicing, RNA stability or 
translation, as well as acting as miRNA decoys (see 23 and references therein). 
lncRNAs are difficult to study en bloc because (i) they cannot be predicted solely on 
their sequence and (ii) the functionality and molecular mode of action of most 
lncRNA family members remains poorly understood. 
 
While mounting evidence indicates important roles for ncRNAs in hepatic 
dedifferentiation, their dynamics and functional effects have not been quantitatively 
assessed with high temporal resolution. Therefore, we here thoroughly characterized 
changes in coding and non-coding transcriptomes during dedifferentiation of PHH 
using unsupervised whole transcriptome analyses. We detected massive alterations of 
ncRNA signatures that preceded changes in coding transcripts during later stages of 
dedifferentiation. In order to investigate whether these ncRNA modulations could 
drive the dedifferentiation process, we established a miRNA inhibition assay using 
two chemically-distinct inhibitors that interfere with different nodes of the miRNA-
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processing pathway. We found that miRNA inhibition significantly reduced the early 
miRNA response and the loss of hepatic marker genes. Moreover, whole-
transcriptome analyses revealed that gene expression changes during dedifferentiation 
in inhibitor-treated samples were globally reduced, thus providing strong evidence for 
the importance of ncRNAs, in particular miRNAs, in hepatic dedifferentiation. 
 
 
Materials and Methods 
Hepatocytes cultures  
Fresh hepatocytes obtained from patients subject to liver resections at Huddinge 
University Hospital, Stockholm, Sweden were used for the dedifferentiation 
experiments (Table 1). The hepatocytes obtained from patient livers were isolated as 
previously described24. Use of liver specimens was approved by the Ethics Committee 
at Karolinska Institutet and written informed consent was obtained from all donors of 
liver material. Hepatocytes were seeded into plates coated with 5 µg/cm2 Rat Tail 
Collagen Type I (Corning) in culture medium (Williams E medium supplemented 
with 2mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 10 µg/ml 
insulin, 5.5 µg/ml transferrin, 6.7 ng/ml sodium selenite, 100nM dexamethasone) with 
10% FBS. After two hours of attachment, the medium was replaced with serum-free 
culture medium. Time point 0 (t0) is defined as immediately before plating. The other 
time points denote time passed since plating.  
 
miRNA inhibition experiments 
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Cryopreserved hepatocytes were thawed according to the supplier’s protocol 
(BioreclamationIVT) and cultured as above. Cells were treated with 2 (low), 10 
(medium) or 30 µM (high) AF or 1 (low), 5 (medium) or 15 µM (high) PLL as 
indicated.  
 
Statistical analyses 
Unsupervised hierarchical clustering and principal component analysis of genes was 
performed in Qlucore Omics Explorer 3.2. Differentially expressed genes were 
determined using an F-test across all time points (omnibus ANOVA). Multiple testing 
correction was performed using the Benjamini-Hochberg algorithms with a false 
discovery rate (FDR) of 1%. For correlations between mRNA and protein responses, 
Pearson correlation coefficients were computed on fold changes of mRNA and 
protein abundances at the respective time points relative to t0. Pathway analyses were 
performed using Ingenuity Pathway Analysis (IPA, QIAgen). Global gene expression 
data from control and AF/PLL-treated PHH were used to extract miRNA expression 
levels that were further normalized to t0. Corresponding fold-change values for 
upregulated miRNAs were interpreted in the microRNA Target Filter of IPA to find 
corresponding downregulated mRNA targets from whole transcriptome data of the 
same samples. Resulting gene lists were submitted to the WebGestalt online resource 
for KEGG pathway analysis25.  
 
Extended methods are available in the Supporting Information online. 
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Results 
Transcriptomic changes occur in two distinct phases of molecular remodeling 
during hepatocyte dedifferentiation. 
To decode the changes in transcriptional profiles during dedifferentiation of PHH we 
analyzed assessed gene expression dynamics using whole transcriptome approaches in 
which coding as well as non-coding RNA transcripts were analyzed with high 
temporal resolution (n=3-5 livers per time point). In total, we identified 4,042 
transcripts that were significantly differentially expressed during the first 24 hours of 
dedifferentiation after multiple testing correction (FDR=0.01, Figure 1A). 
Importantly, we detected two distinct phases of transcriptomic changes: an early 
response (from 30 minutes until 4 hours) and a late response (between 16 and 24 
hours) that were characterized by changes in two distinctively different sets of genes 
(Figure 1B). 
 
Pathway analyses of differentially expressed transcripts over time revealed significant 
modulations of cytokine and signal transduction pathways such as IL-1 and PKA 
signaling as well as PPARα/RXRα transcriptional responses already after 30 minutes 
followed by major restructuring of metabolic pathways evidenced by changes in 
oxidative phosphorylation and mitochondrial dysfunction (Figure 1C and Supporting 
Table 2). The earliest responses were detected in genes involved in innate immunity, 
whereas expression changes in genes involved in absorption, distribution, metabolism 
and excretion (ADME) of drugs as well as cell adhesion were found at later phases 
(Supporting Figure 1). Furthermore, alterations in EIF2 signaling and protein 
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ubiquitination pathways suggest modulations of protein turnover. Significant changes 
at later stages of hepatic dedifferentiation included major metabolic pathways such as 
the TCA cycle, ketogenesis, the urea cycle and fatty acid metabolism.  
 
To probe whether transcriptomic alterations were faithful markers of phenotypic 
changes during dedifferentiation, we performed whole-proteome analyses. Overall, 
we detected significantly less expressed proteins than coding transcripts (2,356 
proteins vs. 20,667 transcripts) most likely due to the low expression levels of many 
proteins such as transcription factors as well as the relatively lower sensitivity of mass 
spectrometry-based methods. To assess the agreement between responses on mRNA 
and protein level, we correlated transcriptomic and proteomic changes. Interestingly, 
while correlations were poor after 4 hours (r=0.16), they improved substantially after 
24 hours (r=0.72; Figure 1D). Notably, abundances of most CYP proteins, such as 
CYP2A6, CYP2B6, CYP2C19 and CYP2D6 were only moderately affected after 24 
hours of dedifferentiation in agreement with long half-lives of this class of 
proteins11,26, whereas their corresponding transcript levels were strongly reduced. The 
overall proteomic changes followed transcriptomic profiles with the exception of fatty 
acid β-oxidation, which was first detected at the proteomic levels (Figure 1C and 
Supporting Table 3). We concluded that changes in transcriptomic signatures translate 
into phenotypic changes during early hepatocyte dedifferentiation and are thus 
suitable markers to study underlying regulatory processes.  
 
When we categorized differentially expressed transcripts into protein-coding genes, 
miRNAs, lncRNAs, snoRNAs and ribosomal genes (rRNAs and ribosomal proteins, 
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we observed that changes in these ncRNA classes peaked at 4 hours, whereas an 
impact on coding genes was predominantly observed later (Figure 2). Furthermore, 
whereas protein-coding genes showed a tendency to be rather downregulated during 
dedifferentiation (52.4% downregulated), non-coding genes were predominantly 
upregulated (Figure 2C-F). Interestingly, among the different classes of ncRNAs, the 
dynamics and direction of regulation of lncRNAs Figure 2D) more closely resembled 
the temporal and directional profiles of coding genes (Figure 2B), possibly, at least in 
part, because of a positive correlation between the transcription of lncRNA and their 
proximal protein-coding genes27.  
 
miRNA levels are substantially reduced in primary hepatocytes upon small 
molecule inhibition of the miRNA machinery. 
Based on the dynamics and direction of transcriptomic changes, we hypothesized that 
modulations of the ncRNAome could be causal for alterations observed in protein-
coding genes and thus for the loss of the hepatocyte phenotype. To test this 
hypothesis, we focused specifically on miRNAs since miRNA biogenesis and action 
is mediated by only few genes that constitute the miRNA processing machinery. We 
inhibited the miRNA pathway at two distinct nodes using two well-characterized, 
chemically distinct compounds, acriflavine (AF) and poly-L-lysine (PLL). While PLL 
is reported to inhibit the association of pre-miRNAs to Dicer, AF impairs RISC by 
inhibition of miRNA binding to AGO family proteins28. No toxicity of AF and PLL 
was detected at any of the concentrations tested after 4 hours (p>0.15 for all, 
Supporting Figure 2). After 24 hours, PLL affected viability only minimally even at 
high concentrations (viability PLLhi = 86%±4%), whereas AF was more toxic with 
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increasing concentrations.  Consequently, we chose to focus on samples treated with 
low AF (viability AFlow = 71%±4%) and high PLL concentrations, respectively. 
 
First, we assessed the effect of AF and PLL on expression levels of a set of specific 
miRNAs with important roles in liver function (Figure 3A). Hepatic miRNAs miR-
103 and miR-107 that regulate insulin sensitivity29 were upregulated during 
dedifferentiation, an effect that was inhibited by PLL and to a lesser extent by AF. 
Similarly, levels of the pro-proliferative miRNAs miR-21, miR-122 and miR-221, 
which target the cell cycle inhibitors BTG2, HMOX1 and CDKN1B30-32, respectively, 
were rapidly increased, consistent with an initiation of the hepatic regeneration 
program. No significant changes were detected in the anti-proliferative miR-22 and 
miR-26a (p>0.05 for both miRs after 4 and 24h compared to t0, data not shown). Yet, 
levels of the anti-proliferative miRNA miR-33a, a direct inhibitor of CDK6 and 
CCND133 were massively increased during dedifferentiation. Importantly, PLL and 
AF generally reduced the burst of miRNA expression observed in untreated samples, 
indicating that small molecule inhibition of the miRNA machinery might be an 
effective means to reduce overall miRNA levels.   
 
Next, we assessed the effect of AF and PLL on miRNA levels on a global scale and 
detected a decrease in overall miRNA expression levels (Figure 3B). While after 4h, 
12% (AF) and 7% (PLL) of all expressed miRNA were downregulated >1.5-fold, 
after 24h 32% (AF) and 43% were downregulated upon AF and PLL treatment, 
respectively compared to control at the same time point (Figure 3C), thus confirming 
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that inhibition of the miRNA machinery results in substantially reduced levels of 
mature miRNAs in the cell within the time frame studied.  
 
Inhibition of the miRNA machinery delays the loss of hepatic differentiation 
markers 
To address the impact of miRNA inhibition during hepatic dedifferentiation, we 
assessed whether AF- and PLL-mediated miRNA inhibition impacts hepatocyte 
dedifferentiation kinetics. We analyzed the changes in expression levels of 110 genes, 
including phase I and phase II enzymes, transporters, nuclear receptors and other 
genes with importance for hepatic functionality (Figure 4). We found that expression 
of these hepatic genes decreased rapidly in untreated hepatocytes with some genes 
being downregulated by up to 97% (SLCO1B1 and SLCO1B3) after only 4 hours of 
culture (Figure 4B). Importantly, inhibition of the miRNA machinery largely 
mitigated the loss of marker gene expression (Figure 4 and qPCR validations in 
Supporting Figure 3). Consistent with the downregulation of hepatic genes during 
dedifferentiation, expression levels of the vast majority of these genes were found to 
be increased compared to untreated controls at the same time point (Figure 4C). We 
noticed that effect sizes of our treatments differed substantially between genes, as 
expression levels of CYP3A4 and HNF4A increased only to a limited extent, whereas 
the effect on CYP2C8 and CYP2C9 was much more prominent (Figure 4A and 
Supporting Figure 3). 
 
To substantiate the conceptual role of miRNAs in dedifferentiation, we specifically 
inhibited miR-103, a miRNA that was strongly affected by AF and PLL treatment, 
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using specific antagomiRs (Supporting Figure 3). We found that expression of its 
bona fide target gene CYP2C834 was significantly increased, thus providing evidence 
that candidate miRNA inhibition can contribute to a delay of dedifferentiation when 
only considering its particular target transcript subset.  
 
We conclude that while the extent and kinetics to which hepatic marker genes are 
regulated by miRNAs can differ, inhibition of the miRNA machinery has overall 
profound effects on dedifferentiation at the molecular level. 
 
 
miRNA inhibition reduces overall hepatocyte dedifferentiation. 
To assess the impact of miRNA inhibition during dedifferentiation beyond alterations 
of expression patterns in hepatic markers, we correlated expression fold-changes for 
each gene after 4 hours and 24 hours of dedifferentiation in control with PLL- and 
AF-treated samples (Figure 5). The slope of the regression lines indicates the extent 
of dedifferentiation for a given treatment and time-point relative to control. After only 
4 hours, transcriptomic signatures were significantly different between control and 
inhibitor-treated samples (p<0.0001, F-test comparing control and AF/PLL regression 
lines). In inhibitor-treated samples, expression levels were generally less affected 
compared to control (95% CI of regression slopes: (aPLL,4h) = 0.7-0.71; 95% CI(aAF,4h) 
= 0.76-0.76; Figure 5A,B), an effect became even more pronounced over time as 
transcriptomic fingerprints more closely resembled samples prior to dedifferentiation 
than dedifferentiated control samples after 24 hours of culture (95% CI(aPLL,24h) = 
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0.24-0.25; 95% CI(aAF,24h) = 0.27-0.28; Figure 5C,D). Furthermore, when considering 
only genes that were found to be differentially expressed during dedifferentiation (see 
Fig. 1), we found that changes in their gene expression signatures, indicative of 
dedifferentiation were drastically reduced (Supporting Figure 5).  
 
While transcriptomes of treated and control samples correlated significantly 
(p<0.0001 for both AF and PLL, F-test), the expression levels of some individual 
genes differed drastically. When considering only those genes whose expression 
levels were increased >10-fold in miRNA-inhibitor treated samples, we found them to 
be enriched in both AF- and PLL-treated samples in acute phase response signaling, 
the complement system, FXR/RXR and PXR/RXR activation, thus suggesting 
prolongation of immune response signaling and a positive effect on liver specific 
functionality (see Supporting Table 4). Genes that were downregulated >10-fold in 
inhibitor-treated samples were , among others, enriched in adherence junction, 
signaling, the actin cytoskeleton and ILK signaling. Again, very similar results were 
obtained using both AF and PLL. 
 
Interestingly, transcriptomic changes in response to inhibition of the miRNA 
machinery were mostly symmetrically distributed in up- and downregulated genes 
compared to control (Supporting Fig. 6). Nevertheless, the fraction of genes that were 
downregulated less in treated compared to control samples was enriched especially 
after 24 hours (red columns, Supporting Fig. 6).  
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We then analyzed the effects of AF and PLL specifically on the miRNAome and 
associated pathways by matching upregulated miRNAs with their predicted target 
transcripts within the same experiment (Table 2). In control samples, metabolic 
pathways, protein processing in the endoplasmic reticulum and fatty acid metabolism 
were most significantly affected. Importantly, significantly fewer genes of the 
respective networks were targeted in AF- and PLL-treated samples in agreement with 
overall reduced dedifferentiation. 
 
Combined, our data indicate that inhibition of the miRNA machinery results in drastic 
changes in the hepatic dedifferentiation program, strongly reducing the loss of hepatic 
markers and mitigating alterations in adherence junction signaling and cytoskeletal 
remodeling, suggesting a key role for miRNAs in driving the underlying molecular 
processes.  
 
 
Discussion 
Hepatocytes are very dynamic cells in vivo that can rapidly switch between non-
dividing states during liver homeostasis and dividing states upon liver injury. During 
this process, they undergo a wide range of molecular changes including alterations in 
marker gene expression, indicating that they can transiently dedifferentiate into more 
progenitor-like states8,9. Following proliferation, cells redifferentiate and thus 
replenish the pool of mature hepatocytes within the regenerating organ9. Mechanistic 
understanding of how hepatocytes can alter their differentiation states can give 
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valuable information for the generation of hepatocytes from stem cells. 
Dedifferentiation also occurs in vitro as rapid loss of marker gene expression and 
hepatic functionality are observed when PHH are placed in 2D culture. This loss of 
liver functions is detrimental in drug discovery and assessment programs where new 
chemical entities are tested e.g. for metabolism, toxicity, drug interactions and 
induction, as results are considered a reliableform the basis for the development of 
clinical programs and the use of the potential drug compounds34.  
 
In this study, we demonstrate that gradual changes in genes related to immunity and 
energy balance occurred during the first 4 hours of culture, followed by later changes 
in major metabolic pathways. Notably, the response at the proteomic level mostly 
overlapped and followed transcriptomic changes with respect to pathway 
enrichments, indicating that transcriptomic changes are overall faithful markers of 
phenotypic alterations in the early phases of hepatocyte dedifferentiation. 
Interestingly, transcriptomic and proteomic responses correlated only very weakly 
after 4 hours (r=0.16), probably at least in part due to the widespread transcriptomic 
remodeling, which has not been fully translated to the level of protein abundances. In 
contrast, correlations after 24 hours are significantly higher (r=0.72) and similar to 
values reported for murine liver (r=0.6 for mRNA vs. protein copy numbers)35. 
 
When expression changes were resolved by gene class, the highest number of 
differentially expressed genes was detected after 4 hours of culture. Notably, the 
upregulation of ribosomal genes was paralleled by an activation of mTOR and EIF2 
signaling, which primes cells for increased mRNA translation, foreshadowing a 
Page 55 of 93
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
HEP-16-0352.R2 22
massive remodeling of cellular functionality and phenotypes36,37. Furthermore, the 
canonical function of snoRNAs is the 2’-O-methylation and pseudouridylation of 
ribosomal RNAs, again hinting at an overall translational activation18.  
 
To functionally test the role of non-codingmi RNAs as potential drivers of the 
dedifferentiation program, we used AF and PLL. PLL inhibits Dicer-dependent and 
thus the processing of pre-miRNA molecules into mature single-stranded miRNAs, 
manifesting in reduced miRNA levels28, which is consistent the global reduction in 
miRNA levels (Figure 3). In contrast, AF blocks the binding of mature miRNA 
molecules to AGO family proteins and hence does not directly impact miRNA 
levels28. Yet, previous studies showed that unbound miRNAs are less stable than 
miRNAs bound to RISC38, which could explain the variability in expression levels of 
the different miRNAs. The extent of reduction in expression upon inhibitor treatment 
varied substantially between different miRNAs. While miR-33a levels were below 
detection limit upon PLL treatment already after 4 hours, levels of miR-21 were not 
affected, suggesting vastly different miRNA half-lives. This finding is interesting 
ascontrasts previous studies that reported that miRNAs are very stable with half-lives 
ranging to range from hours to days, indicating that the inherent stability might differ 
miRNA species but also between primary cells during major remodeling processes 
and cell cultures in static culture conditions39. Notably, the slow kinetics of genetic or 
siRNA-based approaches for miRNA-inhibition combined with long half-lives of 
protein components of the miRNA machinery40 render such tools inadequate to inhibit 
miRNA action within the timeframe in which molecular changes occur. Therefore, 
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small molecule inhibition presents currently the only viable option to perturb rapidly 
enough.  
 
While hepatocytes proliferate in vivo after partial hepatectomy, dedifferentiation in 
vitro is not paralleled by hepatic proliferation. Even when cells are stimulated with 
growth factors, proliferation quickly ceases and cells enter cell cycle arrest41. This 
discrepancy between proliferative responses in vivo and in vitro correlates with the 
differences in response of miR-33 as expression of this miRNAwhose expression is 
reduced during liver regeneration, relieving inhibition of CDK6 and Cyclin D1 
expression thereby supporting entry of cells into mitosis. In contrast,, whereas in vitro 
miR-33a expression is strongly increased in vitro as indicated above(Figure 3A), 
hampering cell cycle entry. Thus, inhibition of miR-33a might present a novel 
approach to stimulate proliferation of primary hepatocytes in vitro. 
 
Importantly, analyses of expression kinetics of 110 hepatic genes revealed that their 
downregulation was mostly reduced with both miRNA inhibitors, yet to varying 
extents (Figure 4 and Supporting Fig. 3). While the decrease in e.g. CYP2A6, 
CYP2C8, CYP2C9, CYP2D6 and SLC22A1 expression was strongly reduced, only 
minor elevations of transcript levels were observed for CYP3A4. Our results are in 
agreement with previous experimental findings experimentally showing that CYP2C8 
(miR-103/107) and CYP2C9 (miR-128) are strongly regulated by miRNAs34,42. 
Furthermore, a recent screen for miRNAs as modulators of CYP3A4 activity revealed 
only minor inhibition43 consistent with the low but significant increase in CYP3A4 
transcript levels observed here. To validate these findings, we inhibited miR-103 
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using a specific antagomiR and found that its bona fide target gene CYP2C8 was 
upregulated accordingly during dedifferentiation (Supporting Figure 4). These 
experimental indications about the extent to which miRNAs regulate ADME gene 
expression further incentivizes their therapeutic targeting and warrants investigations 
of the impact of miRNAs on the disposition of co-administered drugs44. Yet, further 
studies are required to quantify the recruitment of specific miRNAs to the RISC, as 
bound miRNAs might be more faithful reporters for regulatory load during liver 
regeneration than overall transcriptional levels45Yet, further studies will be needed to 
quantify the extent of regulation exerted by specific miRNAs as recruitment of mature 
miRNAs to the RISC rather than overall transcriptional levels might be more faithful 
reporters for miRNA regulatory load during liver regeneration4445.  
 
Combined, our data indicate that (i) an upregulation of a multitude of miRNAs 
precedes the loss of hepatic marker gene expression and (ii) that this dedifferentiation 
is diminished when the miRNA pathway is either generally inhibited or when 
candidate miRNAs are blocked in a targeted approach. Importantly though, not all 
hepatic markers that we analyzed responded to miRNA inhibition with similar 
magnitude indicating that also other regulatory mechanisms such as short transcript 
half-lives potentially contribute to a rapid downregulation of transcript levels.  
 
When we correlated expression fold-changes in control and miRNA inhibitor-treated 
samples, we found that the ameliorating effect on dedifferentiation increased after 24 
hours, possibly due to indirect effects such as the regulation of core transcription 
factors (Figure 5). The pathways that were mMost strongly considerably “rescued” 
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pathways by miRNA inhibition were complement system and cytokine signaling, 
cytoskeleton, cell adhesion, and hepatic expression programs such as PXR/RXR 
activation (Figure 5C,D), thus mirroring deregulated pathways during 
dedifferentiation and indicating an overall improvement of hepatic phenotype. While 
the data presented here indicates that miRNA changes constitute an integral part of 
the hepatic dedifferentiation program, the upstream cues that trigger the initiation of 
dedifferentiation, remain to be elucidated.  To this end, a variety of stimuli have been 
suggested, including the harsh hepatocyte isolation procedure conditions as such, 
serum depletion, alterations in ECM interfaces cell-ECM or cell-cell contacts and 
exposure to non-physiological stiffness of culture substratum46,47.  However, as 
hepatocytes retain their functionality when cultured as 3D spheroids in serum-free 
conditions48However, based on results that functionality is retained when isolated 
hepatocytes are cultured as 3D spheroids in serum-free conditions47, the alterations in 
ECM interfacesperturbations of cell-ECM or cell-cell contacts and exposure to non-
physiological stiffness of culture substratum appear to be the most likely 
explanationscauses.  
 
The data presented here might exemplify a more general biological principle of 
dynamic cellular adaptation. miRNAs might serve as the tool of choice for the cell to 
quickly degrade particular mRNA and/or inhibit their translation, especially those 
with a long half-life, and thus facilitate expeditious remodeling of the transcriptomic 
inventory when rapid adjustments are needed in response to changes in environment 
or specific signaling cues as seen in other contexts, such as T-cell activation49. 
Furthermore, as miRNAs can have pleiotropic targets thereby diversifying an 
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incoming stimulus into a wide range of downstream targets, thus serving as a 
molecular signal amplifier. 
 
In conclusion, our results indicate a novel role for miRNAs in hepatic processes and 
implicate them as important drivers of hepatic dedifferentiation. As such, these 
findings are of importance for understanding mechanisms of stem cell differentiation 
into hepatocytes as well as for liver regeneration, during which similar 
dedifferentiation processes might occur in vivo. Furthermore, the data presented here 
might highlight a more wide-spread miRNA-mediated dynamic control of 
transcriptional profiles that warrants further investigations. 
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Figure 1: Profiling of early events in hepatic dedifferentiation on transcriptomic 
and proteomic level reveals overall molecular rearrangements.  (A) Heatmap 
visualization of mean-centered, sigma-normalized expression data of differentially 
expressed genes during the first 24 hours of hepatocyte dedifferentiation (n=4,042, 
FDR=0.01) reveals an early response in which expression changes accumulate 
progressively during the first 4 hours and (ii) a later response in which a different set 
of genes was affected. Numbers in the colored circles indicate the respective 
hepatocyte donor (Table 1). (B) Principle component analysis of differentially 
expressed genes shown in A resulted in the identification of two orthogonal 
components for early and late transcriptomic changes. (C) Pathway analysis of 
differentially expressed genes revealed thea temporal order of events. Pathways 
identified as differentially regulated in at least 2 consecutive time points with p<0.05 
on transcriptomic level (blue) and proteomic level (red) are shown in blue and on 
proteomic level in red. Only differentially regulated pathways that were identified in 
at least 2 consecutive time points with p<0.05 are shown. (D) Scatter plots showing 
the correlations between mean changes in mRNA levels and the corresponding 
average changes in protein abundances after 4 hours and 24 hours in culture. The 
mean of 3 donors is plotted. 
 
Figure 2: Early changes in non-coding RNAs precede rearrangements of the 
coding transcriptome during hepatocyte dedifferentiation. (A) Stacked column 
plot visualizing the number of up- and downregulated genes at each time point 
compared to t0. Coding genes are shown in blue, non-coding genes in grey. Small pie 
charts associated to each column indicate the relative fractions of differentially 
expressed non-coding RNAs at the respective time point categorized by gene class. 
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Note that the highest number of differentially expressed genes was found after 4 hours 
and was dominated by upregulated non-coding RNAs. (B-E) Stacked column plots 
showing the profiles of transcriptomic changes resolved by gene class and up- and 
downregulation (dark and light hue, respectively) into protein-coding genes (B), 
miRNAs (C), lncRNAs (D), snoRNAs (E) and ribosomal genes (F). y-axis indicates 
differentially expressed genes. While protein-coding genes were up- and 
downregulated, non-coding genes had a strong bias for upregulation especially at 
early time points.  
 
Figure 3: miRNA expression during hepatocyte dedifferentiation can be 
inhibited using small molecule inhibitors. The miRNA machinery was inhibited 
using acriflavine (AF) and poly-L-lysine (PLL). All expression levels were 
normalized to expression prior to dedifferentiation (t0). (A) Expression of all six 
miRNAs shown were elevated during dedifferentiation in control samples (blue). This 
increase in miRNA levels was mostly inhibited dose- dependently by AF (red) and 
PLL treatment (green). Inhibitor- treated samples were compared with the 
corresponding controls at the same time point using heteroscedastic two-tailed t-tests. 
Error bars indicate s.e. * indicates p<0.05, ** indicates p<0.01. n.d. indicates 
expression below detection limit. N=6 experiments for controls and 3 for inhibitor- 
treated samples (B, C) Transcriptomic assessment of miRNA levels upon AF- and 
PLL-treatment. (B) Heatmap displaying expression changes of all detected miRNAs. 
(C) Column plot showing the fraction of expressed miRNAs that were downregulated 
more than 1.5-fold compared to control at the same time point. In total n=210 
different miRNAs were robustly detected in all samples. 
Page 62 of 93
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
HEP-16-0352.R2 29
 
Figure 4: Inhibition of the miRNA machinery ameliorates changes in hepatic 
genes during hepatic dedifferentiation. (A) Heatmap visualization of mean-
centered, sigma-normalized expression data of 110 genes with importance for hepatic 
functionality. Note that while many hepatic genes are rapidly lost in control samples, 
treatment with AF and PLL overall decreases this effect.  (B, C) Dot plot 
representations visualizing the change of expression of the same 110 hepatic genes 
compared to timepoint 0 (B) or to the corresponding control at the same time point 
(C). Notably, CYP2A6, a specialized indicator of hepatic differentiation11, is 
upregulated 8- and 26-fold in AF and PLL-treated samples after 24h, respectively. FC 
= fold change. 
 
Figure 5: Evaluation of overall transcriptomic changes in response to miRNA 
inhibitors reveals drastically reduced dedifferentiation. Scatter log-plots of 
transcriptomic changes (n=61,933 gene products) in control samples versus changes 
in AF- or PLL-treated cultures after 4 h (A-B) and 24 h (C-D). Red and green dots 
highlight genes that are up- or downregulated >10-fold under treatment, r spectively. 
These form the basis for the analysis of most affected pathways shown in red and 
green inlet boxes. Solid red lines indicate complete dedifferentiation in control 
samples (slope a=1). Dashed red lines indicate computed regression lines. Note that 
regression line slopes (ainh) can be interpreted as the extent of dedifferentiation and 
were <1 for all time points and treatments, indicating decreased overall 
dedifferentiation at the systems level. Values for r indicate Pearson correlation 
coefficients.  
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Profiling of early events in hepatic dedifferentiation on transcriptomic and proteomic level reveals overall 
molecular rearrangements.  
Figure 1  
210x226mm (300 x 300 DPI)  
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Early changes in non-coding RNAs precede rearrangements of the coding transcriptome during hepatocyte 
dedifferentiation.  
Figure 2  
210x173mm (300 x 300 DPI)  
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miRNA expression during hepatocyte dedifferentiation can be inhibited using small molecule inhibitors.  
Figure 3  
210x246mm (300 x 300 DPI)  
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Inhibition of the miRNA machinery ameliorates changes in hepatic genes during hepatic dedifferentiation.  
Figure 4  
210x187mm (300 x 300 DPI)  
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Evaluation of overall transcriptomic changes in response to miRNA inhibitors reveals drastically reduced 
dedifferentiation.  
Figure 5  
210x162mm (300 x 300 DPI)  
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Table 1: Demographic information of primary human hepatocyte donors used in 
this study. 
Donor Gender Age Indication Viability of 
isolated cells 
1 male 31 Primary scleroting 
cholangitis and 
cholangiocarcinoma 
74% 
2 male 36 Acute intermittent 
porfyria 
93% 
3 male 70 Colon cancer metastasis 87% 
4 female 69 Colon cancer metastasis 74% 
5 female 63 Colon cancer metastasis 70% 
 
Page 75 of 93
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Table 2: Most differentially regulated pathways in hepatocyte dedifferentiation 
identified by matching changes in miRNA expression with its putative target 
transcripts. The table lists the top 10 KEGG pathways affected in dedifferentiation 
with the corresponding number of downregulated genes. Indicated p-values are 
obtained after correction for multiple testing. padj ≤0.05 were considered significant. 
n.s. indicates not significantly affected pathways (padj >0.05). 
KEGG pathways 
 
4h ctrl 
vs t0 
 
4h PLL 
vs t0 
 
4h AF 
vs t0 
 
Metabolic pathways 248 
(padj=5*10-53) 
139 
(padj=2*10-16) 
64 
(padj=2*10-3) 
Protein processing in endoplasmatic reticulum 52 
(padj=3*10-17) 
37 
(padj=3*10-11) 
21 
(padj=1*10-6) 
Fatty acid metabolism 24 
(padj=2*10-14) 
10 
(padj=1*10-3) 
n.s. 
Valine, leucine and isoleucine degradation 23 
(padj=4*10-13) 
13 
(padj=2*10-5) 
6 
(padj=0.02) 
Glycine, serine and threonine metabolism 18 
(padj=5*10-11) 
7 
(padj=0.01) 
n.s. 
TCA cycle 17 
(padj=2*10-10) 
11 
(padj=1*10-5) 
n.s. 
Complement and coagulation cascades 25 
(padj=5*10-10) 
10 
(padj=0.02) 
7 
(padj=0.03) 
Drug metabolism – cytochrome P450 25 
(padj=2*10-9) 
11 
(padj=0.01) 
n.s. 
Peroxisome 26 
(padj=2*10-9) 
19 
(padj=4*10-6) 
11 
(padj=3*10-3) 
Tryptophan metabolism 17 
(padj=8*10-8) 
8 
(padj=0.01) 
n.s. 
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Supporting Figure 1: Expression kinetics of a selection of genes involved in innate immunity, hepatic metabolism and 
cell adhesion. Heatmap visualizations of mean-centred, sigma-normalized expression data of genes involved in innate 
immunity (A), drug absorption, distribution, metabolism and excretion (ADME; B), and cell adhesion (C), undergoing rapid 
changes upon hepatocyte dedi!erentiation. Data presented are averages from primary human hepatocytes from three 
di!erent individual livers.
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Supporting Figure 2: Impact of AF and PLL treatment on viability. Column plot 
showing the relative viability of samples treated with di!erent concentrations of AF and 
PLL after 4 h and 24 h compared to untreated control samples at the same respective 
time point. N=3 experiments. Viability was determined by MTT assay. Heteroscedastic 
two-tailed t-tests were performed to compare treated samples with the corresponding 
controls at the same time point. Error bars indicate s.e. * corresponds to p<0.05, ** to 
p<0.01. Changes in viability were considered not signi"cant (n.s.) when p>0.05. 
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Supporting Figure 3: Inhibition of the miRNA machinery results in a delayed loss of candidate hepatic mark-
ers. The miRNA machinery was inhibited using acri!avine (AF) and poly-L-lysine (PLL). All expression levels were 
normalized to expression prior to dedi"erentiation (t0). qRT-PCR analysis of candidate hepatic marker genes encom-
passing key metabolic genes (CYP2C8, CYP2C9, CYP2D6 and CYP3A4), secretory products (ALB), hepatic transcription 
factors (HNF4A, NR1H4) and cellular transporters (SLC22A1 and SLCO1B1) con#rmed our transcriptomic results that 
treatment with AF or PLL increased overall expression levels of marker genes after 4 h and 24 h. N = 4 experiments. 
Heteroscedastic two-tailed t-tests were performed to compare inhibitor treated samples with the corresponding 
controls at the same time point. Error bars indicate s.e. * indicates p<0.05, ** indicates p<0.01. 
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Supporting Figure 4
Supporting Figure 4: Downregulation of miR-103 recovers the expression of CYP2C8 during 2D dedi!erentia-
tion. (A) PHH were transfected with !uorescently labeled microRNA Hairpin Inhibitor Transfection Control (Dy547 
miRIDIAN, Dharmacon) and were analyzed 24 h post transfection by immuno!uorescence microscopy. Scale bar = 50 
µm. (B) PHH were transfected with miR-103 antagomiR and total RNA was isolated 24 h post transfection. Subse-
quently, CYP2C8 mRNA levels were quanti#ed by qRT-PCR and normalized to cells transfected with the control 
antagomiR. Note that CYP2C8 expression was rescued dose-dependently with increasing amounts of miR-103 antag-
omiR. Heteroscedastic two-tailed t-tests were performed to compare antagomiR-treated samples with the controls 
to which they were normalized. * indicates p<0.05; n=3.
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Supporting Figure 5: E!ect of miRNA inhibition on genes that were found to be di!erentially expressed 
during dedi!erentiation. All genes (n=4,042) that were identi"ed as di#erentially expressed during hepatocyte 
dedi#erentiation (omnibus ANOVA, FDR=0.01, see Figure 1) were included in the analysis shown. (A) Heatmap visual-
ization of mean-centered, sigma-normalized expression data of di#erentially expressed genes upon miRNA inhibi-
tion with AF or PLL. (B) Principle component analysis of transcriptomic changes in control and inhibitor-treated 
samples. Note that while the early response is only mildly a#ected, progression to later stages of dedi#erentiation is 
strongly inhibited.
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Supporting Figure 6: Inhibition of the miRNA machinery results in decreased downregulation of transcripts. 
Semilog-transformed histograms showing the extent of up- (red) and downregulated genes (blue) in PLL (A, B) and 
AF (C, D) treated samples after 4 h (A, C) and 24 h (B, D). Expression levels compared to t0 are shown on the x-axis 
using a bin-size of 0.2. Histograms were calculated using a rotation matrix around the control expression angle using 
Python. Note that the distribution of upregulated genes in AF and PLL is negatively skewed indicating an increased 
fraction of genes that were downregulated but to a lesser extent than in control samples consistent with a reduction 
of the inhibitory miRNA e!ect. 
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Supporting Methods 
 
 
Materials 
Cell culture medium and supplements were purchased from Sigma. Hyclone 
Fetal Bovine Serum (FBS) was purchased from Thermo Scientific. Acriflavine 
(AF, #01673) and poly-L-lysine (PLL, #P6516) were purchased from Sigma. 
Stock solutions were made in nuclease-free water and added directly to the 
culture medium. 
 
Proteomics  
Hepatocytes were washed and gently scraped into ice-cold phosphate buffer (pH 
7.4) followed by centrifugation at 2000g for 5 minutes. The supernatants were 
discarded and the cell pellets were stored at -80°C until analysis. Each cell pellet 
was thawed and lysed by sonication in a volume of 0.5 M triethylammonium 
bicarbonate (TEAB)/0.1% sodium dodecyl sulfate (SDS) that is equivalent to cell 
pellet volume. The cell lysates were then centrifuged at 14,000g for 15 minutes 
at 4°C and the supernatants were recovered. For the liver samples, 50-100 mg of 
tissue per sample was homogenized in 0.5 M TEAB/0.1% SDS using a Mixer Mill 
220 (Retsch, Haan, Germany) followed by sonication as per the hepatocyte 
samples. Protein concentrations were determined by the Bradford assay.  
Prior to labelling, 100 µg of protein from each sample was reduced with 2.5 mM 
tris-(2-carboxyethyl) phosphine for 1 h at 60°C, alkylated with 10 mM s-methyl 
methanethiosulfonate (MMTS) for 10 minutes at room temperature and digested 
with 10 µg trypsin overnight at 37°C. The tryptic digests from each sample were 
labelled with one of the individual 8-plex-iTRAQ tags (iTRAQ Reagents Multiplex 
kit; Sciex, Framingham, Massachusetts) for 2 h at room temperature. The 
labelled samples were then pooled, the pH adjusted to <3 and the labelled 
peptides were separated on a polysulfoethyl A (200 x 4.6 mm, 5 µm, 200 Å; 
PolyLC Columbia, Maryland) strong cation exchange column. Cation exchange 
chromatography was performed on an Agilent 1100 system using Buffer A (10 
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mM KH2PO4 in 25% ACN, pH 3.0) and Buffer B (10 mM KH2PO4, 1 mM KCl in 25% 
ACN, pH 3.0)  for a 95 minute gradient from 0-15% B and with a flow rate of 1 
mL/minute. Collected fractions (2mL) were dried using a vacuum concentrator 
and resuspended in 40 µL of 0.1% formic acid prior to mass spectrometry 
analysis. 
Peptide fractions (5 µL) were injected into an Eksigent cHiPLC Nanoflex system 
equipped with a trap column (C18-CL 3 µm, 0.5 mm, 120 Å) and a separation 
column (C18-CL 3 µm, 75 µm X 15 cm, 120 Å ChromXP). A 90 minute gradient 
from 2% ACN/0.1% formic acid to 50% ACN/0.1% formic acid was applied at a 
flow rate of 300 nL/min. MS analysis was performed on a TripleTOF 5600 
system (Sciex) in positive ion mode and via information dependent acquisition.  
Survey scans of 250 ms were used to trigger full-scan MS/MS acquisition of the 
25 most intense ions with an accumulation time of 100 ms (total cycle time 2.8 
s).  A threshold for triggering of MS/MS of 100 counts per second was used, with 
dynamic exclusion for 12 seconds and rolling collision energy adjusted for the 
use of iTRAQ reagent in the Analyst method.  Mass ranges of 400-1600 atomic 
mass units (amu) in MS and 100-1400 amu in MS/MS were used.  The 
instrument was calibrated after every fifth sample using a beta-galactosidase 
digest resulting in mass accuracy of <10ppm. Data was processed using 
ProteinPilot 4.5 software (Sciex) and the Paragon algorithm against the latest 
UniProt database (release 2014_06, 20,213 human entries) with iTRAQ as a 
variable modification, MMTS as the cysteine alkylating reagent and biological 
modifications allowed. The reversed database was used as a decoy to determine 
the false discovery rate (FDR) for protein identification, and only those proteins 
identified within a 1% FDR were evaluated further. Ratios for each iTRAQ label 
were obtained using a pooled sample as a reference which consisted of combined 
aliquots of each individual sample tested. 
 
Viability measurement 
Cell viability was measured using the EZ4U cell proliferation and cytotoxicity 
assay (Biomedica) according to the manufacturer’s instructions. 100 µl of dye 
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solution was added to 1 ml of sample and incubated at 37°C. After 2 h 150 µl 
medium was transferred to a clear 96-well plate and absorbance was measured 
at 450 nm and 492 nm using a microplate reader. Values were normalized 
against absorbance of blank medium with or without AF or PLL at the same 
wavelength. 
 
Gene expression analysis 
PHH were lysed directly in the culture dish and total RNA was extracted. 
Expression of candidate genes and miRNAs was analyzed by quantitative real-
time PCR (qRT-PCR) using the TaqMan probes specified in Supporting Table 1. 
For miRNA analysis, RNA was reverse transcribed using either the TaqMan 
MicroRNA Reverse Transcription Kit (miR-103, 107, 122) or the newer TaqMan 
Advanced miRNA cDNA Synthesis Kit (miR-21, 22, 26a, 26b, 33a, 221; both kits 
from Applied Biosystems). The relative abundance of each miRNA was estimated 
using the ΔCt method and normalized using the housekeeping small nucleolar 
RNA RNU44 (miR-103, 107, 122) and miR-320a (all other miRNAs) following the 
manufacturers protocol. For whole transcriptome analyses, we used GeneChip 
Human Transcriptome Arrays 2.0 (Affymetrix) following the manufacturer’s 
instructions. 
 
miRNA antagomiR transfection 
PHH were transfected with miRIDIAN microRNA human hsa-miR-103a-3p 
inhibitor or microRNA Hairpin Inhibitor Transfection Control (Dharmacon) 
using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) according to 
the manufacturer’s guidelines.  
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Supporting Table 1: Overview of the TaqMan Assays used. 
 
 
TaqMan assay Product number 
(Thermo Fisher) 
ALB Hs00910225_m1 
CYP2C8 Hs02383390_s1 
CYP2C9 Hs02383631_s1 
CYP2D6 Hs02576168_g1 
CYP3A4 Hs00604506_m1 
HNF4A Hs00604431_m1 
NR1H4 Hs01026590_m1 
SLC22A1 Hs00427552_m1 
SLCO1B1 Hs00272374_m1 
TBP Hs00427620_m1 
hsa-miR-103a-3p 4427975-000439 
hsa-miR-107 4427975-000443 
hsa-miR-122-5p 4427975-002245 
hsa-miR-22-3p 477985_mir 
hsa-miR-26a-5p 477995_mir 
hsa-miR-221-3p 477981_mir 
hsa-miR-33a-5p 478347_mir 
hsa-miR-21-5p 477975_mir 
hsa-miR-26b-5p 478418_mir 
hsa-miR-320a 477802_mir 
RNU44 snoRNA 4427975-001094 
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Supporting Table 2: Overview of differentially regulated pathways and their 
corresponding gene constituents on transcript level. Pathways identified as 
differentially regulated on transcriptomic level by IPA, their p-value and the genes 
contained in each pathway are shown (compare Figure 1C).  
 
Ingenuity 
Canonical 
Pathways 
-log(p-
value) 
Molecules 
30 min 
 
PPARa/RXRa 
Activation 
4.19 TGFBR2, ADCY9, TGFB1, PRKAR2A, IL1B, NR2C2, MEF2C, 
MAP2K3, PRKAR1A 
IL-1 Signaling 3.70 GNB1, ADCY9, FOS, PRKAR2A, MAP2K3, PRKAR1A 
Protein Kinase A 
Signaling 
2.68 AKAP12, GNB1, TGFBR2, ADCY9, FLNA, TGFB1, PTPRB, 
PRKAR2A, PRKAR1A 
1h 
 
EIF2 Signaling 6.65 PABPC1, PIK3CA, RPL17, RPS10, EIF4G3, RPS21, EIF2S3, 
EIF4A2, RPL26, EIF3E, EIF4G1, EIF2A, FAU, RPL9, RPL27, 
RPL27A, RPL8, RPL18A, EIF3B, EIF3I, RPL19, RPL21, RPS27A, 
INSR, RPL18, RPL13A, EIF3K 
Oxidative 
Phosphorylation 
6.25 SDHA, ATP5G1, COX7B, ATP5H, NDUFA7, COX6A1, COX5B, 
NDUFB5, ATP5L, SDHC, NDUFA2, NDUFB3, ATP5C1, NDUFB9, 
NDUFA6, NDUFB6, NDUFS2, NDUFA12, NDUFS3, ATP5F1 
Protein 
Ubiquitination 
Pathway 
5.68 USP24, DNAJB4, UBR2, UBE3B, SKP1, DNAJC8, HSPE1, USP47, 
PSMA2, AMFR, PSMA6, USP15, UBE2Q1, UBE4B, PSMD13, 
DNAJC19, USP9X, BIRC6, PSMA1, PSMD8, PSMB7, PSME1, 
UBE2H, USP32, USP22, DNAJB11, PSMA5, UBR1, BAP1, USP34, 
BIRC2 
Mitochondrial 
Dysfunction 
5.05 SDHA, ATP5G1, FURIN, COX7B, ATP5H, NDUFA7, COX6A1, 
COX5B, NDUFB5, ATP5L, SDHC, VDAC3, NDUFB3, NDUFA2, 
APP, ATP5C1, NDUFB9, PRDX3, NDUFA6, NDUFB6, NDUFS2, 
NDUFA12, NDUFS3, ATP5F1, PINK1 
PPARa/RXRa 
Activation 
2.33 GNAS, GNAQ, NR2C2, MED12, ABCA1, NCOA3, PRKAG1, 
TGFBR2, ADCY9, TGFB1, PRKACA, IL1B, MEF2C, NCOR1, 
MAP2K3, INSR, RXRA, MAP4K4, PRKAR1A 
IL-1 Signaling 1.69 GNAI2, GNB1, ADCY9, IL1A, GNAS, PRKACA, GNAQ, 
MAP2K3, PRKAG1, PRKAR1A 
Protein Kinase A 
Signaling 
1.53 AKAP12, FLNB, PTPRK, GNAS, YWHAE, GNAQ, PRKAG1, 
PTPRF, AKAP11, ROCK1, YWHAQ, ROCK2, GNAI2, TGFBR2, 
AKAP2, GNB1, ADCY9, PTPN11, TGFB1, PTPRB, PRKACA, 
ADD1, PRKAR1A, DUSP16 
PXR/RXR 
Activation 
1.43 PRKACA, ABCB11, INSR, RXRA, ABCC3, PAPSS2, PRKAG1, 
SLCO1B3, PRKAR1A 
2h 
 
Oxidative 
Phosphorylation 
3.97 SDHA, SDHB, NDUFA9, ATP5H, COX6A1, COX5B, NDUFB5, 
ATP5L, NDUFA2, ATP5C1, NDUFA6, NDUFA12, NDUFS3, 
ATP5F1, ATP5G3 
Protein 
Ubiquitination 
Pathway 
3.67 USP24, UBE4B, USP15, DNAJB4, PSMD13, UBR2, UBE3B, 
USP9X, DNAJC12, BIRC6, PSMA1, PSMD8, PSMB7, PSME1, 
USP32, UBE2B, USP22, DNAJC8, USP47, HSPE1, PSMB1, BAP1, 
USP34, BIRC2 
Mitochondrial 3.61 SDHA, FURIN, SDHB, ATP5H, NDUFA9, COX6A1, COX5B, 
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Dysfunction NDUFB5, ATP5L, BACE1, NDUFA2, APP, ATP5C1, PRDX3, 
NDUFA6, NDUFA12, NDUFS3, ATP5F1, ATP5G3, PINK1 
EIF2 Signaling 3.06 PIK3CA, RPL17, RPS10, EIF4G3, EIF4A2, EIF4G1, EIF2A, FAU, 
RPL8, RPL35, EIF1, RPL18A, EIF3I, RPL19, INSR, RPL18, ATM, 
EIF3K 
PPARa/RXRa 
Activation 
2.64 CD36, GNAQ, PRKAR2A, NR2C2, IL6, MED12, ABCA1, NCOA3, 
PRKAG1, TGFBR2, ADCY9, TGFB1, MEF2C, NCOR1, INSR, 
RXRA, MAP4K4, PRKAR1A 
Protein Kinase A 
Signaling 
2.53 AKAP12, FLNB, PTPRK, YWHAE, PDE3A, GNAQ, PRKAR2A, 
ANAPC13, PHKA2, PTPRF, PRKAG1, AKAP11, TGFBR2, 
YWHAQ, ROCK2, GNB1, AKAP2, ADCY9, NFAT5, PTPN11, 
TGFB1, PTPRB, ADD1, PPP3CA, PRKAR1A 
PXR/RXR 
Activation 
1.36 PRKAR2A, ABCB11, INSR, IL6, RXRA, ABCC3, PRKAG1, 
PRKAR1A 
4h 
 
Mitochondrial 
Dysfunction 
9.69 MAP2K4, FURIN, XDH, ACO2, NDUFB5, ATP5L, NCSTN, 
NDUFA1, NDUFB3, PDHA1, MAOB, NDUFS1, ATP5F1, 
NDUFS7, ATP5A1, BACE1, SDHC, UQCR11, ATP5C1, PRDX3, 
NDUFA6, NDUFB7, VDAC1, NDUFS3, ATP5G1, COX7B, SDHB, 
ATP5H, COX6A1, NDUFA7, NDUFA2, NDUFB9, ATP5J2, 
NDUFS2, NDUFB6, OGDH, CASP8, AIFM1, NDUFS4, SDHA, 
NDUFV1, COX6B1, GLRX2, MAPK8, VDAC3, APP, NDUFV2, 
COX7A2, SDHD, CYCS, PINK1, PSEN1, MAOA 
EIF2 Signaling 9.20 RPL11, RAF1, MAPK1, RPL39, EIF2A, EIF3B, EIF4G2, RPL19, 
RPL21, ATM, PABPC1, EIF2AK1, RPL29, EIF4G3, RPL12, EIF3E, 
RPL37A, RPL9, RPL15, RPL8, INSR, RPL41, RPL13A, EIF3K, 
PIK3CA, RPS3A, RPL26, EIF4G1, RPL27A, RPL35, RPL18A, 
EIF3A, RPS3, RPS5, RPL31, RPL18, RPS24, GRB2, RPL17, RPS10, 
RPS21, RPS29, FAU, RPL27, EIF3G, RPS26, RPS27A, RPL37, 
EIF3L, RPL38 
Oxidative 
Phosphorylation 
6.84 SDHB, COX7B, ATP5G1, ATP5H, COX6A1, NDUFA7, NDUFB5, 
ATP5L, NDUFA1, NDUFB3, NDUFA2, NDUFB9, NDUFS1, 
ATP5J2, NDUFS2, NDUFB6, ATP5F1, NDUFS4, SDHA, NDUFV1, 
COX6B1, NDUFS7, ATP5A1, SDHC, UQCR11, ATP5C1, 
NDUFV2, NDUFA6, NDUFB7, COX7A2, SDHD, CYCS, NDUFS3 
Protein 
Ubiquitination 
Pathway 
5.25 USP45, PSMA7, UBE3B, UBR2, DNAJC15, SKP1, UBE2B, USP10, 
PSMA2, PSMA6, DNAJB12, UBE4B, UBE2Q1, USP9X, DNAJC19, 
PSMD5, BIRC6, PSMB7, USP32, PSMB2, UBR1, BAP1, PSMB1, 
ANAPC5, DNAJB6, UBE2E1, USP24, USP12, UBE2N, DNAJC12, 
ANAPC10, CDC23, HSP90B1, HSPE1, USP16, USP47, PSMA3, 
PSMD14, AMFR, USP15, UBE2R2, PSMA1, DNAJB9, PSMD8, 
UBE2J1, USP4, DNAJB11, USP22, PSMD2, BTRC, USP34, 
UBE2D3, BIRC2 
TCA Cycle 2.36 SDHA, SDHB, SUCLG1, ACO2, SDHD, SDHC, MDH1, OGDH, 
IDH3B 
PXR/RXR 
Activation 
1.52 PPARA, PRKAR2A, CES2, HMGCS2, UGT1A1, PAPSS2, 
ALDH1A1, ALDH3A2, PRKACA, NCOA1, ABCB11, INSR, 
RXRA, ABCC3, TNF, SLCO1B3, PRKAR1A 
mTOR Signaling 1.45 TSC1, PIK3CA, MAPK1, RPS3A, PPP2CA, EIF4G1, PRR5L, 
PDGFC, MTOR, EIF3B, EIF4G2, TSC2, EIF3A, RPS3, RPS5, 
EIF4B, ATM, RPS24, RHEB, STK11, RPS10, EIF4G3, RPS21, 
EIF3E, RPS29, PPP2R5A, FAU, EIF3G, RPS26, RPS27A, INSR, 
EIF3L, EIF3K 
16h 
 
EIF2 Signaling 16.90 RPL11, RPL39, KRAS, EIF4A2, EIF2A, EIF1, EIF4G2, EIF3D, 
PAIP1, EIF5, RPL21, RPL19, RPS2, RPL36AL, RPL29, RPL12, 
EIF2S3, EIF3E, RPL37A, RPL28, RPL9, RPL15, RPL8, INSR, 
RPL13A, RPL41, EIF3K, RPSA, RPLP1, RPS3A, RPS18, RPL26, 
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RPL7, RPS4X, RPL27A, RPL35, RPL18A, RPS17, RPS3, RPS5, 
RPL31, RPL18, RPS24, RPL4, NRAS, EIF3H, RPL17, RPS10, 
RPL30, EIF3J, RPS21, RPS29, FAU, EIF3G, RPL27, RRAS2, 
RPS26, EIF3I, RPS27A, RPL37, RPL38, RPLP0 
Protein 
Ubiquitination 
Pathway 
6.04 USP45, PSMA7, UBR2, SKP1, HSPA5, TCEB1, UCHL5, NEDD4L, 
PSMB5, UBE4B, USP9X, HSPA9, PSMD5, PSMC4, BIRC6, 
PSMD6, DNAJC2, PSMB7, PSMD11, UBE2L3, PSMA5, PSMD12, 
PSMB1, ANAPC5, PSMA4, HSP90AA1, PSMD4, UBE2E1, USP24, 
USP12, USP14, PSMD7, UBE2N, PSMD9, UBE2F, USP3, 
PSMD10, HSPE1, USP16, PSMA3, PSMD14, HSPA4L, PSMB4, 
UBE2M, PSMD13, DNAJC1, PSMA1, HSPD1, DNAJB9, PSMD8, 
PSMD2, CDC34, USP25, DNAJC7, BIRC2 
mTOR Signaling 4.26 RPS3A, PPP2CA, RPS18, KRAS, EIF4A2, PDGFC, PRKAG1, 
RPS4X, EIF4EBP1, EIF4G2, EIF3D, TSC2, RPS2, RPS17, RPS5, 
RPS3, PRKD3, RPS24, RPS6KB1, RHEB, NRAS, EIF3H, RPS10, 
EIF3J, RPS21, EIF3E, RPS29, PLD1, PPP2R5A, FAU, EIF3G, 
PPP2CB, PPP2R1A, RRAS2, PRKCI, RHOQ, RPS26, EIF3I, 
RPS27A, INSR, EIF3K, RPSA, PRKCB 
Fatty Acid b-
oxidation I 
3.72 ACAA1, ACAA2, SCP2, ACSL5, AUH, HADHB, IVD, EHHADH, 
ACADM, HSD17B4, HADH, HADHA, ACSL1 
Ethanol 
Degradation II 
3.02 ADH6, ALDH2, ADH1A, ALDH3A2, ADH1C, ADH1B, PECR, 
ALDH9A1, ACSL1, ADH4 
PXR/RXR 
Activation 
2.99 PPARA, CYP3A7, GSTA2, CYP2C9, CES2, HMGCS2, UGT1A1, 
PRKAG1, PAPSS2, SULT2A1, ALDH3A2, PRKACA, ABCB11, 
G6PC, INSR, RXRA, ABCC3, TNF, SLCO1B3, PRKAR1A, 
CYP2C8 
Mitochondrial 
Dysfunction 
2.37 MAP2K4, FURIN, ATP5G1, NDUFA9, COX6A1, NDUFA7, XDH, 
NCSTN, NDUFA2, VDAC2, PDHA1, NDUFS1, MAOB, NDUFB9, 
SOD2, NDUFS2, HTRA2, CASP8, COX4I1, AIFM1, NDUFA8, 
SDHA, NDUFV1, GLRX2, MAPK8, BACE1, VDAC3, APP, 
ATP5C1, NDUFA6, CAT, CYC1, CYCS, MAOA, PINK1 
Ketogenesis 2.10 BDH1, HADHB, HMGCL, HMGCS2, HADHA 
Urea Cycle 1.31 OTC, CPS1, ARG1 
24h 
 
Fatty Acid b-
oxidation I 
10.20 HSD17B10, SLC27A2, ACAA1, ACAA2, HSD17B8, SLC27A5, 
SCP2, ECI2, ACSL5, AUH, HADHB, EHHADH, IVD, ACADM, 
HSD17B4, HADHA, ACSL1, HADH 
Ethanol 
Degradation II 
7.11 HSD17B10, ADH6, ALDH2, ADH1A, ALDH4A1, AKR1A1, 
ALDH3A2, ADH1C, ADH1B, PECR, ACSL1, ALDH9A1, ADH4 
PXR/RXR 
Activation 
5.54 PPARA, CYP3A7, GSTA2, CYP2C9, CES2, HMGCS2, UGT1A1, 
PRKAG1, SULT2A1, CYP1A2, CYP3A4, PCK2, ALDH3A2, 
NR1I3, ABCB11, GSTA1, G6PC, TNF, SLCO1B3, PPARGC1A, 
CYP2C8, PRKAR1A 
Ketogenesis 3.82 BDH1, ACAT1, HADHB, HMGCL, HMGCS2, HADHA 
Urea Cycle 2.79 OTC, ASL, CPS1, ARG1 
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Supporting Table 3: Overview of differentially regulated pathways and their 
corresponding gene constituents on protein level. Pathways identified as 
differentially regulated on proteomic level by IPA, their p-value and the genes 
contained in each pathway are shown (compare Figure 1C). For proteomic analyses, a 
fold-change threshold of 2 was applied. 
 
 
Ingenuity Canonical 
Pathways 
-log(p-
value) 
Molecules 
2h 
 
Fatty Acid b-oxidation 
I 
7.23 ACAA1, SCP2, ECI2, EHHADH, ACAA2, ECI1, HADH 
Mitochondrial 
Dysfunction 
5.72 ATP5J, SDHB, PRDX3, NDUFS1, SOD2, ATP5H, ATP5D, 
PARK7, TXN2, NDUFS2, UQCRFS1 
Oxidative 
Phosphorylation 
4.00 ATP5J, SDHB, NDUFS1, ATP5H, ATP5D, NDUFS2, 
UQCRFS1 
4h 
 
Mitochondrial 
Dysfunction 
11.30 SDHA, ATP5J, NDUFV1, ATP5H, ATP5D, COX5B, NDUFA2, 
NDUFS1, PRDX3, SOD2, NDUFV2, TXN2, ATP5J2, 
UQCRFS1, NDUFS2, CYCS, CYB5A, UQCRC1, ACO1, 
AIFM1, MAOA 
Oxidative 
Phosphorylation 
9.37 SDHA, ATP5J, NDUFV1, NDUFS1, ATP5H, NDUFV2, 
ATP5D, COX5B, ATP5J2, NDUFS2, UQCRFS1, CYCS, 
CYB5A, UQC C1, NDUFA2 
Fatty Acid b-oxidation 
I 
8.10 ACAA1, SCP2, ECI2, HADHB, HSD17B4, ACAA2, ECI1, 
HADHA, HADH 
TCA Cycle 3.96 SDHA, DHTKD1, DLST, MDH2, ACO1 
PPARa/RXRa 
Activation 
1.33 HSP90B1, GPD1, ACAA1, HSP90AB1, PDIA3, FASN, GOT2 
24h 
 
Mitochondrial 
Dysfunction 
9.82 HSD17B10, SDHA, ATP5J, NDUFV1, ATP5H, ATP5D, 
COX5B, ATP5A1, NDUFS1, PRDX3, SOD2, NDUFS8, 
NDUFV2, PARK7, UQCRFS1, NDUFS2, CYCS, UQCRC1, 
ACO1, NDUFS3, MAOA, AIFM1 
Ethanol Degradation II 9.76 ADH6, ADH5, HSD17B10, ALDH4A1, ADH1A, AKR1A1, 
ALDH1A1, ADH1C, ADH1B, ADH4 
Oxidative 
Phosphorylation 
7.69 SDHA, ATP5J, NDUFV1, ATP5H, ATP5D, COX5B, ATP5A1, 
NDUFS1, NDUFV2, NDUFS8, NDUFS2, UQCRFS1, CYCS, 
UQCRC1, NDUFS3 
Urea Cycle 5.14 OTC, ASS1, ASL, ARG1 
TCA Cycle 4.48 SDHA, DLST, DLD, MDH1, MDH2, ACO1 
Fatty Acid b-oxidation 
I 
2.81 HSD17B10, ACAA1, HADHB, ACAA2, ECI1 
Ketogenesis 2.67 ACAT2, ACAT1, HADHB 
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Supporting Table 4: Overview of affected pathways under AF and PLL 
treatment after 24 hours. Pathways identified as differentially regulated by IPA, 
their p-value and the genes contained in each pathway are shown (compare Figure 
4C,D). Only genes that changed >10-fold were considered. Only pathways that were 
significant after correction for multiple testing are shown (FDR=0.05). 
 
 
 
Ingenuity Canonical 
Pathways 
-log(p-
value) 
Molecules 
Upregulated in PLL 
 
Acute Phase Response 
Signaling 
11.10 HAMP, HPX, ITIH3, C3, C9, CP, C5, PLG, KLKB1, 
FOS, MBL2, ITIH2, APCS, ITIH4, CRP, A2M 
Complement System 10.70 MBL2, C3, C9, CFI, C8B, C6, CFH, C8A, C5 
Coagulation System 7.24 F11, PLG, KLKB1, SERPINC1, F9, F5, A2M 
FXR/RXR Activation 6.31 PON1, HPX, C3, APOF, ITIH4, C9, ABCB11, G6PC, 
PON3, PPARGC1A 
PXR/RXR Activation 5.35 ABCB11, CYP2A6 (includes others), G6PC, IGFBP1, 
HMGCS2, CYP2C8, PPARGC1A 
Intrinsic Prothrombin 
Activation Pathway 
5.21 F11, KLKB1, SERPINC1, F9, F5 
LPS/IL-1 Mediated Inhibition 
of RXR Function 
4.75 CAT, ABCB11, FABP1, CYP2A6 (includes others), 
HMGCS2, CYP4A11, ACSL1, ABCA1, CYP2C8, 
PPARGC1A 
LXR/RXR Activation 4.67 PON1, HPX, C3, APOF, ITIH4, C9, PON3, ABCA1 
Systemic Lupus 
Erythematosus Signaling 
3.02 FOS, C9, C8B, C6, C8A, C5 
Urea Cycle 2.86 CPS1, ARG1 
Histidine Degradation III 2.86 HAL, AMDHD1 
Ethanol Degradation II 2.86 ADH1B, ACSL1, ADH4 
Histidine Degradation VI 2.69 HAL, AMDHD1 
Upregulated in AF 
 
Complement System 10.70 MBL2, C9, CFI, C8B, C6, CFH, C8A, C5 
Acute Phase Response 
Signaling 
7.03 HAMP, PLG, MBL2, ITIH2, APCS, ITIH4, C9, CRP, 
A2M, C5 
Serotonin Degradation 6.34 ADH6, UGT2B7, ADH1B, UGT2B10, ADH4, UGT2B15 
FXR/RXR Activation 4.84 PON1, SLC10A1, APOF, ITIH4, C9, G6PC, PON3 
Coagulation System 4.10 PLG, SERPINC1, F9, A2M 
Nicotine Degradation III 3.61 UGT2B7, UGT2B10, CYP2C8, UGT2B15 
Melatonin Degradation I 3.61 UGT2B7, UGT2B10, CYP2C8, UGT2B15 
Superpathway of Melatonin 
Degradation 
3.49 UGT2B7, UGT2B10, CYP2C8, UGT2B15 
Ethanol Degradation II 3.44 ADH6, ADH1B, ADH4 
Nicotine Degradation II 3.42 UGT2B7, UGT2B10, CYP2C8, UGT2B15 
Thyroid Hormone Metabolism 
II (via Conjugation and/or 
Degradation) 
3.30 UGT2B7, UGT2B10, UGT2B15 
Urea Cycle 3.25 CPS1, ARG1 
Noradrenaline and Adrenaline 
Degradation 
3.24 ADH6, ADH1B, ADH4 
Systemic Lupus 
Erythematosus Signaling 
3.12 C9, C8B, C6, C8A, C5 
PXR/RXR Activation 3.06 G6PC, IGFBP1, HMGCS2, CYP2C8 
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LXR/RXR Activation 3.06 PON1, APOF, ITIH4, C9, PON3 
Maturity Onset Diabetes of 
Young (MODY) Signaling 
2.45 SLC2A2, FABP1 
Superpathway of Citrulline 
Metabolism 
2.38 CPS1, ARG1 
4-hydroxybenzoate 
Biosynthesis 
2.12 TAT 
4-hydroxyphenylpyruvate 
Biosynthesis 
2.12 TAT 
Downregulated in PLL 
 
Epithelial Adherens Junction 
Signaling 
4.61 CDH2, CDH1, ACTR3, NRAS, MYH9, TUBB4B, 
TUBG1, TGFB2, ACTN4, TUBB, CLIP1 
14-3-3-mediated Signaling 3.43 YWHAQ, NRAS, TUBB4B, TUBG1, YWHAZ, GSK3B, 
PDCD6IP, SFN, TUBB 
Remodeling of Epithelial 
Adherens Junctions 
3.43 CDH1, ACTR3, TUBB4B, TUBG1, ACTN4, TUBB, 
CLIP1 
tRNA Charging 3.42 NARS, GARS, KARS, FARSB, FARSA 
Sertoli Cell-Sertoli Cell 
Junction Signaling 
3.19 CDH1, NRAS, TUBB4B, ZAK, TUBG1, ILK, GSK3B, 
ACTN4, TUBB, OCLN 
Actin Cytoskeleton Signaling 3.19 ACTR3, NRAS, MYH9, FGF2, RDX, TRIO, ACTN4, 
TMSB10/TMSB4X, MSN, NCKAP1 
RAN Signaling 3.09 KPNB1, KPNA3, CSE1L, KPNA2 
ILK Signaling 2.95 FLNB, RELA, CDH1, PPP2R1A, MYH9, ILK, GSK3B, 
ACTN4, TMSB10/TMSB4X 
Germ Cell-Sertoli Cell 
Junction Signaling 
2.87 CDH2, CDH1, NRAS, TUBB4B, TUBG1, ILK, TGFB2, 
ACTN4, TUBB 
PI3K/AKT Signaling 2.56 YWHAQ, RELA, PPP2R1A, NRAS, YWHAZ, ILK, 
GSK3B, SFN 
Integrin Signaling 1.72 ACTR3, NRAS, CAPNS1, ITGAV, CAV1, ILK, GSK3B, 
ACTN4 
Myc Mediated Apoptosis 
Signaling 
1.66 YWHAQ, NRAS, YWHAZ, SFN, FAS 
Wnt/b-catenin Signaling 1.49 CDH2, CDH1, PPP2R1A, CSNK2A1, ILK, TGFB2, 
GSK3B 
Cyclins and Cell Cycle 
Regulation 
1.49 PPP2R1A, PA2G4, CDK6, TGFB2, GSK3B 
p70S6K Signaling 1.47 YWHAQ, PPP2R1A, NRAS, EEF2, YWHAZ, SFN 
Aryl Hydrocarbon Receptor 
Signaling 
1.47 ALDH1B1, RELA, CYP1A2, NQO1, CDK6, TGFB2, 
FAS 
HIPPO signaling 1.47 YWHAQ, PPP2R1A, YWHAZ, MOB1A, SFN 
Regulation of Cellular 
Mechanics by Calpain 
Protease 
1.43 NRAS, CAPNS1, CDK6, ACTN4 
Regulation of the Epithelial-
Mesenchymal Transition 
Pathway 
1.43 RELA, CDH2, CDH1, NRAS, FGF2, TGFB2, GSK3B 
Downregulated in AF 
 
tRNA Charging 3.09 NARS, LARS, GARS, FARSB, EPRS 
Remodeling of Epithelial 
Adherens Junctions 
2.63 CDH1, ACTR3, TUBB4B, ACTN4, TUBB, CLIP1 
Epithelial Adherens Junction 
Signaling 
2.63 CDH2, CDH1, ACTR3, MYH9, TUBB4B, ACTN4, 
TUBB, CLIP1 
Sertoli Cell-Sertoli Cell 
Junction Signaling 
2.63 SPTBN1, CDH1, TUBB4B, ZAK, ILK, GSK3B, ACTN4, 
TUBB, OCLN 
RAN Signaling 1.62 KPNB1, KPNA3, CSE1L 
ILK Signaling 1.57 FLNB, CDH1, PPP2R1A, MYH9, ILK, GSK3B, ACTN4 
14-3-3-mediated Signaling 1.48 TUBB4B, YWHAZ, GSK3B, PDCD6IP, SFN, TUBB 
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Actin Cytoskeleton Signaling 1.36 ROCK2, ACTR3, MYH9, FGF2, TRIO, ACTN4, MSN 
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